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ABSTRACT
Bacillus subtilis is a probiotic bacterium that can protect against the murinespecific attaching and effacing (A/E) pathogen Citrobacter rodentium. C. rodentium
displays many features observed with the human pathogen enteropathogenic E. coli
(EPEC). Protection by B. subtilis is mediated by exopolysaccharide (EPS), which is
encoded by the epsA-O operon that contains 15 genes. Disruption of one of these genes,
epsH, which appears to encode a putative glycosyltransferase, leads to the loss of
protective capacity by B. subtilis and by EPS. EPS is a major component of the B. subtilis
biofilm and the ΔepsH mutant is unable to form a biofilm. The goal of this project was to
characterize EPS produced by B. subtilis with mutations to the 15 genes of the epsA-O
operon and assess how single deletions to the genes affect phenotype (biofilm formation),
and the capacity to protect mice from disease caused by C. rodentium. We found that
mutations in 13 of the 15 genes eliminated the probiotic activity of B. subtilis, even
though some of the mutants developed biofilms. Our goal is to compare the structures of
EPS from protective and non-protective mutants, and identify a small molecule that can
be used as a therapeutic to prevent disease caused by enteropathogens.
.
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CHAPTER ONE
REVIEW OF LITERATURE
The immunomodulatory benefits from interactions of the immune system with
commensal bacteria in the intestine have long been appreciated (Shanahan 2002). The
gastrointestinal tract (GIT) is colonized by upwards of 1013 to 1014 bacteria, with the
majority of bacteria residing in the colon. Bacteria in the GIT provide the host with
nutrients, extract calories from host food, and modify the host immune system to help
maintain a state of homeostasis (Guarner and Malagelada 2003; Hardy et al. 2013;
Hooper, Littman, Macpherson 2012). Bacteria provide these benefits through production
of a variety of molecules, including polysaccharides, such as polysaccharide A (PSA) of
Bacteroides fragilis, which interacts with the host and induces mucosal tolerance
(Mazmanian et al. 2005). Bacterial carbohydrates, such as PSA from B. fragilis, can be
complex and contain several different sugars linked by glycosidic bonds. In addition, the
carbohydrates can differ in glycosidic linkages (α or β), linear or branched structure, and
degree of polymerization (monomers, oligomers, and polymers), making these
carbohydrates highly diverse.
Perhaps nowhere else is the diversity of carbohydrates greater than in the
substances secreted by bacteria to form a biofilm. Bacterial biofilms, some of which
adhere to host tissue, are a key structure that provides interaction between host and
bacteria. Biofilms are comprised of mono- or multi-species bacterial communities
encased
!
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in

an

extracellular
1!

matrix

(ECM)

!

!
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(Flemming and Wingender 2010; Guttenplan, Blair, Kearns 2010; Sutherland 2001; Vu
et al. 2009). Great diversity are found in the different carbohydrate polymers in the ECM
of bacteria and these structures mediate a high degree of interaction between host and
bacterial communities (Anderson et al. 2003; Fujimura et al. 2010; Hall-Stoodley,
Costerton, Stoodley 2004; Jones and Knight 2012; Macfarlane and Dillon 2007).
Bacterial polysaccharides have also been shown to enhance virulence by allowing
pathogens to evade the host immune system. Two of the best-studied bacterial
polysaccharides are polysaccharide A (PSA), produced by Bacteroides fragilis, and
exopolysaccharide (EPS), produced by Bacillus subtilis, both of which have been shown
to prevent colitis (Jones and Knight 2012; Jones et al. 2014; Onderdonk et al. 1977;
Round and Mazmanian 2010; Tzianabos et al. 1993).
The Gram-positive spore forming soil bacterium B. subtilis, which produces EPS,
exists either as a unicellular planktonic cell or in a nonmotile aggregate biofilm (Lemon
et al. 2008). Mature biofilms consist of non-motile cells encapsulated in an ECM, which
is primarily composed of EPS and poly-N-acetyl-glucosamine (Jones et al. 2014; Roux et
al. 2015). The undomesticated strain of B. subtilis (NCBI 3610) forms colonies with
wrinkled architecture on LB agar plates and a pellicle between the air liquid interface
when grown in liquid medium (Branda et al. 2001; Kearns et al. 2005). Formation of a
biofilm or pellicle is dependent on the production of EPS, which occurs in the cytoplasm
of the cell and is secreted by an unknown mechanism. Following secretion, EPS is
localized in the protein scaffold of the extracellular matrix (Driks 2011; Guttenplan,
Blair, Kearns 2010). Synthesis of EPS is regulated by the genes encoded in the 15-gene
epsA-O operon and the tapA-sipW-tasA operon. Once EPS is produced by B. subtilis it is
!
!
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most likely stabilized by repeating amyloid protein, TasA, on the extracellular surface of
the bacteria. The interaction between EPS and the protein scaffold of TasA and TapA is
unknown (Driks 2011; Guttenplan, Blair, Kearns 2010; Romero et al. 2011).
A single oral dose of B. subtilis spores can protect mice from enteric disease
caused by C. rodentium, and the protective activity is provided by EPS, which is
composed of mannose (~88%) and glucose (12%) (Jones et al. 2014). B. subtilis spores
with deletions to epsH, a glycosyltransferase of the eps operon, and EPS isolated from a
epsH mutant (Jones and Knight 2012; Kearns et al. 2005; McLoon et al. 2011), are
unable to protect from this disease and do not form a biofilm (Jones and Knight 2012).
The goal of this study was to characterize EPS produced by B. subtilis mutants of the 15
gene epsA-O operon and to determine which genes are required for biofilm formation and
which are required for protection from disease caused by C. rodentium.

Gut Host Microbe Interaction
The microbiome or microorganisms that naturally colonize the host cover the skin
and gastrointestinal tract (GIT) and are believed to have become resident microbes during
years of co-evolution (Chung et al. 2012; Hardy et al. 2013; Ley, Peterson, Gordon 2006;
Macfarlane and Dillon 2007; Madan et al. 2012; Nowrouzian et al. 2003). In exchange
for an environment favorable for their growth, host microbes provide nutrients, extract
calories from food, shape the immune system, impact development of allergies, aging,
mood, and alter susceptibility to disease (Bravo et al. 2011; Hardy et al. 2013; Horton et
al. 2015; Thorburn et al. 2015; Wu et al. 2010).
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The human microbiome has considerable species diversity and includes the
genera Bacteroidetes, Actinobacteria, and Firmicutes. As humans age, there are changes
to the microbial populations in the GIT. The microbiota composition fluctuates over the
lifetime of its host due to changes in environment, diet, and infection (Gareau, Sherman,
Walker 2010; Li, Bihan, Methé 2013; Martínez et al. 2015; Saraswati and Sitaraman
2014).
The diet of the host provides a way for bacteria to be introduced to the GIT and
influences the health of the host. Foods rich in metabolites such as butyrate, a short chain
fatty acid, serve as a source of energy for host colonic epithelial cells, and regulate
mucosal gene expression, differentiation and apoptosis (Kelly et al. 2015). These foods,
or prebiotics, also play a role in priming the environment to be favorable for certain
species of bacteria. On the luminal surface of epithelial cells in the GIT, continuous
layers of mucus are secreted from goblet cells. This coating of mucus is between 100200µm thick and protects against adhesion and invasion by harmful bacteria. Often,
mucus secreted by the host has complex carbohydrate structures and can only be
degraded by several hydrolytic enzymes usually sourced from multiple bacteria
(Macfarlane, Bahrami, Macfarlane 2011; Resta-Lenert and Barrett 2003). Mucins, or
heavy molecular weight proteins that coat surface epithelial cells, are extensively
glycosylated, constitutively secreted by goblet cells, and their polymerization provides a
structural foundation for mucus (Hardy et al. 2013). Colonization with certain bacteria,
such as Lactobacillus rhamnosus and Lactobacillus plantarum 299v, can up-regulate
mucin production, thereby preventing attachment by enteropathogens, such as E. coli
O157:H7 (Curtis et al. 2014; Mack et al. 1999). In addition, species previously thought to
!
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exert negative effects on the host, such as Helicobacter pylori, have begun to be
appreciated for their potential benefits. Recent data on the relationship between H. pylori,
thought to be responsible for peptic ulcer disease, noncardia gastric cancer, and
esophageal cancer, may also afford protection against esophageal adenocarcinoma,
allergic asthma and inflammation, rhinitis, and atopy (Blaser and Atherton 2004; Blaser
2008; Macfarlane, Bahrami, Macfarlane 2011; Qiu et al. 2011; Reibman et al. 2008).
Due to the huge diversity of the microbiota, it is difficult to identify which
bacteria are key players in immunomodulation. To better understand the species and
mechanisms on host immunomodulation and immune system development, germ-free
animals, or animals previously unexposed to microorganisms, are used. A benefit to these
animals is that they limit the diversity of the microbiota and provide some degree of
control for bacteria that are introduced to a host (Macpherson and Harris 2004;
Tlaskalová-Hogenová et al. 2011). Once individual species of interest are identified they
can be isolated and used for individualized treatments which can serve as an attractive
alternative to conventional therapies and pharmaceuticals (Macfarlane, Bahrami,
Macfarlane 2011; Thomas, Ockhuizen, Suzuki 2014). The use of beneficial bacteria
involved in alleviation of disease has already led to improved outcomes for diseases of
the GIT. Improved outcomes include repression of pathogenic microbial growth,
prevention of irritable bowel disease (IBD), and prevention of complications from ileal
pouch-anal anastomosis (IPAA) (Fujimura et al. 2010; Gionchetti et al. 2003; Hooper,
Littman, Macpherson 2012; Macpherson and Harris 2004; O'shea et al. 2009; Stecher and
Hardt 2008).

!
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Probiotics
Probiotics, from the Greek ‘pro bios’ (for life), are microbial organisms that
contribute to human health and are implicated for their potential protective effects against
inflammatory bowel disease (IBS), antibiotic associated and infectious diarrhea,
metabolic syndrome, allergic disorders, mood disorders, and cancer (Bravo et al. 2011;
Gareau, Sherman, Walker 2010; Hume 2011; Wang et al. 2015). These microbes can
influence the activity of a number of cells of the innate immune system, including but not
limited to: natural killer T cells, dendritic cells, macrophages, epithelial cells, as well as
cells of the adaptive arm of the immune system such as Th1 cells, Th2 cells, Th17 cells,
Treg cells, and B cells (Hardy et al. 2013; Hooper, Littman, Macpherson 2012). Bacteria
shown to affect these immunomodulatory activities consist of strains from the genera
Lactobacillus, Bifidobacterium, Bacillus, and Pediococcus (Guandalini 2011; Hardy et al.
2013; Hume 2011; Wang et al. 2015). Of these genera, only one, Bacillus, displays
capability to form spores. Spore-producing bacteria can be used as probiotics; spores are
easy to store and are able to survive the gastric acid of the stomach, successfully
colonizing the GIT of the host (Hong, Le, Cutting 2005).
Probiotics have favored niches in the GIT, and these niches are altered when
changes to the diet are made. In the GIT, ‘functional foods/prebiotics,’ non-digestible
food ingredients, such as indigestible dietary fiber/carbohydrates, primes the environment
for probiotics. These non-digestible food ingredients may act cooperatively to selectively
promote the growth and activity of one or more beneficial probiotic species and stimulate
activity of pre-existing commensal bacteria (Perez-Vilar and Hill 1999; Roberfroid et al.
2010; Thorburn et al. 2015).
!
!

!

!

! 7!

Before the probiotic strains responsible for protection and immune-modulation
were identified, the protective benefits of fermented and cultured foods had been
appreciated in fermentation processes throughout history. Fermented and cultured foods
were present in the Middle East, Ancient Greece and Asia because of their ability to
alleviate illness and aid human health (Hume 2011); however, their mechanisms of
protection were not well understood. In 1905, Stamen Grigorov, a Bulgarian
microbiologist, was the first to identify the potential health benefits of Lactobacillus
bulgaricus (Lactobacillus delbrueckii ssp. bulgaricus) (Metchnikoff 1908). In 1908, Ilya
Metchnikoff expanded this finding, developing the hypothesis that human health and
longevity were associated with the ingestion of lactic acid producing bacteria. Thus the
first steps leading to a better understanding of how certain foods protect against disease
was elucidated.
Metchnikoff reasoned that Bulgarian peasants lived longer and consumed large
quantities of sour milk containing cultures of what are now known as Lactobacillus
bulgaricus. In 1954, Werner Kollath proposed the term probiotic to designate “active
substances essential for healthy development of life” (Guarner and Malagelada 2003;
Hume 2011). The term was further modified by Lilly and Stillwell in 1965 to describe the
“substances secreted by one microorganism that stimulate the growth of another” and
again in 1974 by Parker et. al. to include organisms and substances that contribute to
intestinal microbial balance (Hume 2011; Soccol et al. 2010). Currently, probiotics are
identified as live microorganisms which when consumed in adequate amounts, confer a
health effect on the host (FAO/WHO 2002; Sanders 2008).

!
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The term ‘probiotic’ has evolved, but problems with their use persist. Bacteria
found in commercial products continue to be widely mislabeled, and mechanisms of
protection are often poorly characterized (Hong, Le, Cutting 2005; Huys et al. 2013;
Michail et al. 2006; Ngo Thi Hoa et al. 2000; Sanders et al. 2010). Additionally, some
bacteria labeled as ‘probiotics’ may actually do more harm than no treatment at all
(Besselink et al. 2008). Future individualized therapies will benefit from a better
understanding of how probiotics confer protection and identification of which molecules
are responsible for protection. Additionally, individual molecules are generally easier to
directly administer over live active cultures (Lemon et al. 2008; Soccol et al. 2010) and
reduce the risk of potential negative interactions between host and live organisms.

The Extracellular Matrix and Formation of Biofilms
Biofilms are a key structure in the interaction between the host and bacteria.
Biofilms are ubiquitous in nature and are comprised of tightly associated mono- or multispecies bacterial communities that are encased in an extracellular matrix (ECM)
(Flemming and Wingender 2010). The ECM is a primary component of the biofilm and
develops over a series of different stages in response to external signals. In early stages,
planktonic cells congregate at the site of initiation of the biofilm and differentiate into
non-motile, matrix-producing cells that attach to a surface. These non-motile matrixproducing bacteria form bundles, grow, and aggregate. When the environment is not
favorable for the bacterial community, cells lyse or, if they are spore forming bacteria,
produce spores and the biofilm begins to break down (Flemming and Wingender 2010;
Vlamakis et al. 2013).
!
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The formation of a biofilm is regulated at different stages via diverse
mechanisms. A well-studied regulatory mechanism responsible for production of a
biofilm is quorum sensing (QS); the quorum sensing regulatory pathway is known to
influence production of an ECM. Quorum sensing allows cell-cell communication,
expression of required genes in a cell-density dependent manner, and the production,
release, and detection of chemical signaling molecules. There are two QS processes for
bacteria, autoinducer-1 (AI-1), common in intra-species communication and autoinducer2 (AI-2), associated with inter-species interaction (Vu et al. 2009). An example of a QS
peptide is ComX, which functions as a pheromone and triggers production of surfactin,
which is involved in mediating a subpopulation of cells to produce an ECM (Marvasi,
Visscher, Casillas Martinez 2010). However, these are species-specific mechanisms and
are not necessarily general. Disease-causing bacteria often use the molecules of the ECM
to facilitate adherence to host tissues, evade detection by the host immune system, and
prevent phagocytosis (Nwodo, Green, Okoh 2012).
Molecules of the ECM are not all detrimental to the host, and exopolymeric
substances secreted by commensal bacteria can actually protect against disease (Jones et
al. 2014; Mazmanian and Kasper 2006). The best-studied exopolymeric substance is
polysaccharide A (PSA), one of eight distinct polysaccharides synthesized by the
commensal B. fragilis. B. fragilis is a Gram-negative obligate anaerobe, and it has a
capsular polysaccharide complex that co-opts Treg lineage differentiation and induces
mucosal tolerance (Huang, Lee, Mazmanian 2011; Mazmanian et al. 2005). As
mentioned previously, EPS from the commensal B. subtilis is also well studied and
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protective against the enteropathogen C. rodentium (D'Arienzo et al. 2006; Hooper et
al. 2001; McLoon et al. 2011).

Bacterial Polysaccharides and their Immunomodulatory Activities
Over 99% of microorgansims on Earth live within biopolymers (Rehm 2010; Vu
et al. 2009). The first discovery of a bacterial polymer dates back to the mid-nineteenth
century with the discovery of dextran, a microbial polysaccharide in wine, by Louis
Pasteur. Bacterial polysaccharides are diverse structural products composed of
glycosidically-linked

sugars,

and

classified

as

homopolysaccharides

or

heteropolysaccharides. Homopolysaccharides are composed of one monosaccharide in
repeating units (cellulose, curdlan, dextran, levan, pullulan,) while heteropolysaccharides
are composed of two or more monosaccharides and are usually present as multiple copies
of oligosaccharides with three to eight residues (alginate, gellan or xanthan) (Freitas,
Alves, Reis 2011; Galván et al. 2013; Kumar, Mody, Jha 2007; Öner 2013; Ruffing and
Chen 2006).
Bacterial polysaccharides have varying chemical structure and monomer
composition, as well as physiochemical, and rheological properties. A bacterial
polysaccharide from one species of bacteria may vary greatly depending on the strain it is
produced from, making generalizations about the characteristics of polysaccharides
difficult (Öner 2013). The diverse and unique properties of bacterial polysaccharides
makes them attractive molecules in food, pharmaceutical, cosmetic, oil drilling, and
paper manufacturing industries (Rehm 2010; Roca et al. 2015; Schmid, Sieber, Rehm
2015). The production costs associated with microbial EPS are also high and inhibit use
!
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on a wider scale (Freitas, Alves, Reis 2011; Öner 2013; Rehm 2010; Rehm 2015; Roca
et al. 2015). Most carbohydrate food ingredients used today were introduced between
1940 and 1965. Some of the best-studied and commercially exploited bacterial
polysaccharides include alginate, gellan, glucan, guar, hyaluronan, levan, succinoglycan,
and levan (Freitas, Alves, Reis 2011; Galván et al. 2013; Öner 2013; Ruffing and Chen
2006). With annual production of bacterial polysaccharides at an estimated 2,000 tons for
dextran and 100,000 tons of xanthan alone, these bacterial products, their synthesis, and
their properties are of great value to industry (Rehm 2010). Although bacterial
carbohydrates are of high importance, their synthesis, physical properties, and structures
remain poorly characterized.
Elucidation of the structure and composition of polysaccharides are important
because minor changes in structure of the polysaccharide can alter recognition between
host receptor and polysaccharide and the development of disease. Bacteria such as
Neisseria meningitides, Streptococcus pneumonia, group B streptococci, and
Staphylococcus aureus all produce forms of capsular polysaccharides that have varying
levels of virulence. N. meningitides, a gram-negative bacteria, produces multiple
polysaccharides that are serologically distinct. Of the 13 serogroups produced by N.
meningitides, six serogroups (A, B, C, W-135, X, and Y) cause disease (Stephens,
Greenwood, Brandtzaeg 2007; Tzeng and Stephens 2000; Van Kranenburg et al. 1999;
Zughaier 2011). Understanding how changes to bacterial polysaccharide can reduce
virulence is of importance for developing targeted therapeutics. Bacterial polysaccharides
coat the extracellular surfaces of bacteria and contribute to the development of a robust
extracellular matrix and formation of a biofilm (Guttenplan, Blair, Kearns 2010; McLoon
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et al. 2011) and are also often necessary for energy storage, adhesion, and immune
evasion (Kumar, Mody, Jha 2007; Rehm 2010; Schmid, Sieber, Rehm 2015; Sutherland
2001). Extracellular polysaccharides, such as capsular polysaccharides, are known to
enhance virulence (Cuthbertson et al. 2009; Nanra et al. 2013; O'Riordan and Lee 2004;
Stephens, Greenwood, Brandtzaeg 2007) and are implicated in a number of difficult-totreat infectious diseases (Djeribi et al. 2012; Hall-Stoodley, Costerton, Stoodley 2004;
Parsek and Singh 2003; Zegans et al. 2002).
As mentioned above, the best-studied exopolysaccharides with beneficial
immunomodulatory activities are PSA, produced by B. fragilis, and EPS produced by B.
subtilis. EPS produced by B. subtilis, is thought to confer protection through a TLR-4
dependent pathway. Mice injected with EPS develop increased levels of M2 macrophages
(ϕ), which are capable of suppressing T-cell proliferation in vitro. It is important to note
that EPS is not the only bacterial polysaccharide B. subtilis produces. A number of
neutral polysaccharides add to the structure of the exopolymeric matrix including poly-Nacetyl glucosamine (PNAG), and type I (β-2,6-linked D-fructose units) and type II
(fructose and glucose polymer linked by α-glycoside bonds) polymers. Of these bacterial
polysaccharides produced, Type I and II polymers are synthesized outside the cell by the
extracellular enzyme levansucrase and are therefore extracellular polysaccharides (Dogsa
et al. 2013; Marvasi, Visscher, Casillas Martinez 2010; Schmid, Sieber, Rehm 2015).
Although there are other polysaccharides produced by B. subtilis, EPS and PNAG are the
primary components of the ECM (Jones et al. 2014; Roux et al. 2015).
The production of bacterial polysaccharides generally involves multiple
enzymatic
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polymerization/secretion localized in the cell envelope. Presently, there are four
mechanisms known for the production of carbohydrate polymers in bacteria: the
Wzx/Wzy-dependent pathway, the ATP-binding cassette (ABC) transporter-dependent
pathway, the synthease-dependent pathway, and the extracellular synthesis pathway used
by a single sucrase protein.
The biosynthesis pathways of polysaccharides are not fully understood and
different biosynthesis pathways encode multiple types of glycosyltransferases (GTS),
polymerizing and branching enzymes, and sugar modifying enzymes. The majority of
cell-surface bacterial polysaccharides are produced from the Wzx/Wzy dependent
assembly pathway (Islam and Lam 2014). Bacterial polysaccharides from the Wzx/Wzy
pathway include bacterial surface heteropolysaccharides, such as emulsan produced by
Acinetobacter lwoffii, succinoglycan produced by Sinorhizobium meliloti, and the type I
and 4 capsular polysaccharides produced by Escherichia coli. The synthesis of these
molecules by the Wzx/Wzy dependent pathway begins with individual repeating lipidlinked units that are anchored at the inner membrane. The polysaccharide chain grows at
its reducing end and additions are assembled sequentially by a number of GTS at the
cytoplasmic face of the inner membrane (IM). Polysaccharides then translocate across the
cytoplasmic membrane by a Wzx protein, a flippase. Polymerization of the
polysaccharide is also accomplished by a block transfer mechanism that utilizes the
polymerase protein, Wzy. The Wzy protein functions at the periplasmic space and
facilitates the export of the polymer to the extracellular environment where it’s attached
to the bacterial surface as a capsular polysaccharide (CPS) or released as EPS
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(Cuthbertson et al. 2009; Freitas, Alves, Reis 2011; Galván et al. 2013; Rehm 2010;
Schmid, Sieber, Rehm 2015; Yother 2011).
Most CPS are synthesized by the ABC transporter dependent pathway.
Polysaccharides are synthesized by GTSs at the cytoplasmic face of the inner membrane
and depending on the number of GTSs involved, the polysaccharides are either homo or
heteropolymeric. Transport of synthesized CPCs occurs through tripartite efflux pump
complexes that span the inner membrane and periplasmatic proteins (Schmid, Sieber,
Rehm 2015; Whitney and Howell 2013; Willis and Whitfield 2013).
Arguably a less complicated mechanism is the synthase dependent pathway,
which results in secretion of completed polymer strands across the membranes and cell
wall and is independent of a flippase. Polysaccharide polymerization and translocation is
completed by a single synthase protein and products are generally homopolymeric. Some
enzymes in the synthase-dependent pathway are bi-functional and perform both
polymerization and secretion (Schmid, Sieber, Rehm 2015).
While a general understanding of the mechanisms for the synthesis of bacterial
polysaccharides is known, further characterization is necessary to better understand the
enzymes involved in polysaccharide synthesis.

Glycosyltransferases
The large variety and complexity of oligosaccharide and polysaccharide structure
is in part due to the enzymes such as GTSs, glycosidases, glycan phosphorylases, and
polysaccharide lysases, which synthesize their production. GTSs are a class of enzymes
that catalyze glycosidic bond formation and utilize sugar donors with a nucleoside
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phosphate or a lipid phosphate-leaving group (Lairson et al. 2008). There are two
known classes of GTSs that result in retention (retaining GT) or net inversion (inverting
GT) at the anomeric carbon relative to the phospho-sugar donor substrate (Gavin, Jon,
Toone 2009; Lairson et al. 2008). As is true for polysaccharide biosynthesis, the catalytic
mechanisms of GTS are also poorly understood. Additionally, GTSs vary in their
substrate specificity and sequence and are classified into two superfamilies on the basis
of structural fold, GT-A and GT-B. Both GT-A and GT-B GTSs contain Rossman folds
(Gavin, Jon, Toone 2009; Sánchez-Rodríguez et al. 2014), or structural motifs found in
proteins that bind cofactors. Incidentally, SpsA, which is produced by B. subtilis, was the
first GTS shown to adopt a GT-A fold (Lairson et al. 2008).

The epsA-O Operon and Characteristics of EPS
Genes responsible for the production of EPSs are generally clustered (Dertli et al.
2013; Van Kranenburg et al. 1999) and identifiable by the multiple GTSs, polymerases,
and secreting enzymes they encode (Guttenplan, Blair, Kearns 2010; Schmid, Sieber,
Rehm 2015). EPS is produced by 15 different genes encoded in the eps operon of B.
subtilis. The 15 genes encoded in the operon have sequences that suggest a variety of
enzymatic activities including 6 glycotransferases, 2 pyruvyltransferases, as well as a
kinase, flippase, acetyltransferase, and aminotransferase (Roux et al. 2015). At least one
of these genes, epsE, encodes for a bifunctional enzyme that promotes matrix synthesis
and inhibits motility (Guttenplan, Blair, Kearns 2010).
EPS secreted from B. subtilis with a deletion to epsH, a glycosyltransferase, does
not inhibit all C. rodentium associated disease markers, or modulate the immune system
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compared to WT EPS (Jones and Knight 2012; Jones et al. 2014). It is believed that
epsH is an important enzyme that contributes to the formation of a protective EPS. The
use of strains of B. subtilis with deletions to the genes of the eps operon is a unique and
novel approach to identify immunomodulatory forms of a bacterial polysaccharide.

Figure 1. Illustration of the order of the 15 genes of the epsA-O operon. Labels below
the gene indicate the suggested type of enzyme the gene encodes. Red text is to highlight
the large number of putative glycosyltransferases found in the operon.
Citrobacter rodentium as a Model of Enteric Disease
Citrobacter rodentium is a Gram negative (G-) attaching and effacing (A/E)
mouse specific enteropathogen, previously known as Citrobacter freundii (Luperchio et
al. 2000; Schauer et al. 1995). C. rodentium induces actin filled membranous protrusions,
pedestals, at the site of attachment. Following pedestal formation, an A/E lesion forms
and the pathogen breaches the epithelial barrier infecting the host. C. rodentium is used in
infection models in mice to study diseases such as enteropathogenic E. coli (EPEC),
eterohaemorrhagic E. coli (EHEC), Crohn’s, ulcerative colitis (Chandrakesan et al. 2014;
Higgins et al. 1999). These are diseases that have few prophylactic treatments available.
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C. rodentium is genetically similar to the human attaching and effacing (A/E)
pathogens which attach and adhere to the intestinal epithelium, destroy microvilli,
displace commensal microbiota, and deplete goblet cells. C. rodentium shares 67% of
genes with EPEC and EHEC (Petty et al. 2010) including the locus of enterocyte
effacement pathogenicity island (Garmendia, Frankel, Crepin 2005), which encodes
effector proteins and a type III secretion system. It also expresses many of the same
effectors of EPEC and EHEC, such as a type IV pilus, which is known to increase
colonization (Mundy et al. 2003).
Following infection with C. rodentium, mice develop transmissible murine crypt
hyperplasia (TMCH), which is accompanied by intestinal inflammation during colitis.
TMCH is caused by thickening of the colonic mucosa which is a result of excessive
induction of epithelial regeneration and repair mechanisms (Barker, De Wetering,
Clevers 2008; Barthold and Jonas 1977; Luperchio and Schauer 2001; Mundy et al. 2005;
Schauer and Falkow 1993a; Schauer and Falkow 1993b). Mice also develop colitis and
this contributes to the overgrowth of C. rodentium and an overall reduction of total
bacterial diversity in the GIT (Mundy et al. 2005). TMCH is triggered by the loss of
epithelial barrier integrity and the transit of bacteria into the sterile lamina propria. Mice
with TMCH generally experience cycles of biphasic disease (progressive and regressive
phases) that last 2-3 weeks (Chandrakesan et al. 2010; Luperchio and Schauer 2001).
During the progressive phase, fibroblast growth factor 7 and IL-11 are produced by
pericryptal myofibroblasts. Other uncharacterized signals trigger cell proliferation via
activation of WNT-β-catenin, signal transducer and activator of transcription3 (stat3), and
phosphatidylinositol 3-kinase-AKT-β-catenin signaling pathways (Brown et al. 2011;
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Gibson et al. 2010; Papapietro et al. 2013). The regressive phase involves pathogen
clearance and resolution of colitis and inflammation and a return to normal intestinal
homeostasis (Chandrakesan et al. 2010).
Probiotics including Lactobacillus rhamnosus, Lactobacilus helveticus, and
Bifidobacterium breve UCC2003 have been shown to prevent C. rodentium colonization
(Hardy et al. 2013). The gut commensal Bacteroides thetaiotaomicron is thought to
exacerbate infection and increase gut permeability (Curtis et al. 2014) and contribute to
worsening of disease. B. subtilis has been shown to prevent symptoms of disease
(D'Arienzo et al. 2006; Mazza 1994) and it is now believed that EPS produced by B.
subtilis is responsible for protection against C. rodentium associated disease (Jones and
Knight 2012; Jones et al. 2014). Interestingly, protection by EPS is independent of
colonization levels of C. rodentium suggesting that EPS modulates the immune system of
the host (Jones and Knight 2012).

Methods for the Analysis and Study of Complex Carbohydrates
Bacterial polysaccharides can be extremely large and vary in molecular weight (a
few thousand to several million Daltons), and their study requires a unique set of methods
(Cui 2005; Kumar, Mody, Jha 2007). Carbohydrates are heterogeneous and differ in their
primary structure, charge, linkages (α- and β-) and degree of polymerization, and have
macromolecular characteristics including linear and branching structure. These variations
give polysaccharides a number of properties and makes their study difficult.
Successful analysis of polysaccharides relies on the removal of other substances
that interfere with analysis and results are influenced by how the sample was prepared.
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Low molecular weight carbohydrates can be extracted with hot 80% ethanol while
water-soluble polysaccharides can be precipitated with >70% ethanol and a low molarity
salt solution (Benhura and Chidewe 2011; Cui 2005; Davis and Clapp 1961; Eliasson
2006; Healey et al. 2014; Nielsen 2010; Smidsrod and Haug 1967; Weising et al. 2005).
Much of what is known about bacterial carbohydrates comes from their use in
industry (Vu et al. 2009; Walt et al. 2012). Xanthan gum, produced by the bacterium
Xanthomonas campestris, is a unit-repeating polymer and is most likely the best-studied
extracellular polysaccharide. This high molecular weight (3x105-8x106 Da) bacterial
polysaccharide is used in industry and agribusiness and valued for its solubility in either
hot or cold solutions, high viscosity at low concentrations, and cellulose-like backbone.
Although it was cleared for use by the FDA in 1969 and its synthesis has been
extensively studied, the polymerization and export of xanthan is poorly characterized as
is the biosynthesis of other bacterial polysaccharides (Cui 2005; Galván et al. 2013;
Hassler and Doherty 1990; Kumar, Mody, Jha 2007; Roca et al. 2015).
Basic analysis has historically been limited to the presence or absence of
carbohydrate in a sample. Assays such as the phenol-sulfuric acid assay (Dubois et al.
1956) and the anthrone assay are two tests used to determine the presence of
carbohydrate content; however, phenol-sulfuric acid assays are more commonly used
(Nielsen 2010). In the presence of a strong acid and heat, carbohydrates undergo a series
of reactions that lead to the formation of furan derivatives such as furnanaldehyde and
hydroxymethyl furaldehyde. A dehydration reaction is followed by newly formed furan
derivatives which condense with themselves and phenolic compounds if present, and
produce dark colored complexes which can then be measured at 490nm (Nielsen 2010).
!
!

!

!

! 20!

Although useful in detecting carbohydrate in a sample, any measurement of the total
sugar is an estimate based on the reactivity of the sugar used as a standard (historically
glucose) and many different sugars in solution react differently with the assay reagents
(Cui 2005; Nielsen 2010). Additionally, samples can be assayed for the presence of a
carbohydrate via a modified phenol sulfuric acid assay which does not use a phenol
solution and therefore reduces reagents and chemical interaction (Albalasmeh, Berhe,
Ghezzehei 2013). There are also enzymatic methods of analysis but these methods
require a basic knowledge of the polysaccharide composition (Gawehn 1988).
Presently, advances in the field of carbohydrate analysis have created a number of
new methods that enable the determination of the structure of complex polysaccharides.
These include fast atom bombardment mass spectrometry (FAB-MS), matrix-assistant
laser desorption ionization mass spectrometry (MALDI-MS), electrospray ionization
mass spectrometry (ESI-MS), nuclear magnetic resonance (NMR) spectroscopy,
Correlation Spectroscopy (COSY), Total Correlated Spectroscopy (TOCSY), and
Distortionless Enhancement by Polarization Transfer (DEPT). All of these techniques
allow for the solving of structure and composition with some being more precise than
others. A problem that persists is that these methods require specialized equipment and
reference databases that are not always available (Bubb 2003; Cui 2005; Walt et al.
2012). NMR is presently one of the most powerful techniques for carbohydrate analysis.
Use of NMR in conjunction with other analytical methods allows for a characterization of
a complex polysaccharide including detailed structural information of carbohydrates,
identification of monosaccharide composition, elucidation of α- or β- anomeric
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configurations, establishment of linkage patterns, and identification of large polymer
sugar units in oligosaccharides and/or polysaccharides (Bubb 2003; Cui 2005).
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CHAPTER TWO
MATERIALS AND METHODS
Pellicle and Biofilm Formation Assays
To assess pellicle formation of B. subtilis mutants, overnight (O/N) bacterial
starter cultures were diluted 1:100 in a total volume of 2mL per well in a 24-well tissue
culture dish and incubated without agitation for 24 hr at 37°C. Following incubation,
pellicle formations at the air-liquid interface were assessed with bright field microscopy
and photos taken.
To assess biofilm formation, O/N bacterial starter cultures were diluted 1:100 and
25µL was plated onto plates containing Luria-Bertani (LB) media (Difco) with 1.5% agar
(Beckman Dickinson). The plates were incubated without agitation for 24 hr at 37°C.
Biofilm formation was assessed with bright field microscopy and photos taken. Strength
of biofilm formation was quantified by microtiter dish biofilm formation assay as
described by O’Toole (O'Toole 2011). Briefly, 100µL of a 1:100 dilution of starter
culture was plated and incubated for 16 hr. Plates were washed twice with water and
125µL of a 1% crystal violet (CV) solution was added to wells and incubated at room
temperature (RT) for 20 min. Plates were washed with deionized water (dH2O) four times
and 150µL of a 30% acetic acid solution was added to wells of the microtiter plate to
solubilize remaining CV. The 150µL of solubilized CV was then transferred into a new
flat-bottomed microtiter dish and the absorbance of the liquid measured at 550nm.
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Purification of EPS
To isolate and purify EPS produced by B. subtilis mutants, 10mL of LB broth was
inoculated from a frozen glycerol stock and incubated for 16 hr at 250 RPM at 37°C. A
1:1000 dilution of bacterial starter cultures was made in 1L of LB broth and incubated for
16 hr at 37°C. Cultures were pelleted at 4500 x g for 20 min at RT and the supernatant
collected. Supernatants were precipitated with 50% ethanol (EtOH) and incubated O/N at
-20°C. Precipitates were pelleted at 15000 x g for 20 min at 4°C, re-suspended in 100mL
of 0.1M Tris, and treated with DNase (67µg/mL) and RNase (330µg/mL) for 4 hr at
37°C. DNase and RNase digested samples were digested with Proteinase K (40 µg/mL)
for 4 hr at 56°C and precipitated with 100mL 50% EtOH and incubated O/N at -20°C.
Precipitates were pelleted at 15000 x g for 30 min at 4°C.
EPS pellets were re-suspended in 0.1M Tris with a working concentration of
sodium azide and loaded on a size exclusion column with a Sepharcryl 1000 (allyl
dextran and N,N’-methylene bisacrylamide) matrix. Fractions containing EPS were
identified by a modified phenol sulfuric acid assay as described in Albalasmeh et. al.
(Albalasmeh, Berhe, Ghezzehei 2013). Briefly, 30µL of fraction sample volume was
added to a 96-well microtiter dish and 90µL of concentrated H2SO4 (18M) was added to
wells. Microtiter dishes were then placed on the surface of a water bath set at 68°C for at
least 30 min and the absorbance measured at 315 nm on a UV-Vis Spectrophotometer
(BMG Labtech, Omega SPECTROstar).
Phenol sulfuric acid assay positive fractions were pooled and precipitated with
50% EtOH and incubated O/N at -20° C. Precipitates were collected at 15000 x g, resuspended in tissue culture grade water and dialyzed O/N at 4°C in 1L of tissue culture
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grade water. Dialysis cassettes (Life Technologies, Slide-A-Lyzer) with a molecular
weight cut off of 10K were used to remove small impurities, salts, and remaining sodium
azide in EPS samples. Dialyzed samples were precipitated with 50% EtOH O/N at -20°C.
Precipitates were collected at 12500 x g for 20 min at 4°C and dried in a vacuum
centrifuge.
Purified EPS from B. subtilis strains used in this study were re-suspended in 0.1M
Tris or 1X phosphate buffered saline (PBS).

10X PBS
NaCl
2.99 M
NaH2PO4 37 μM
Na2HPO4 168 μM
pH to 6.45

Comparison of EPS Size Isolated from Bacillus subtilis Mutants
To assess the size of pre-column purified EPS from various B. subtilis mutants,
100µL of 50µg/mL EPS was loaded into a fast performance liquid chromatography
(FPLC) apparatus (GE, AKTA protein purification system) with a Superose 6 (agarose
matrix) 10/300 GL Size Exclusion Tricorn column (GE). Solutions of 20mg/mL Blue
Dextran (>2,000KD), 6mg/mL apoferritin (450kD), 6mg/mL IgG (150kD), and a 10M
fructose were also loaded on the column to serve as reference points of size.
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Detection of Similar Epitopes of EPS Isolated from Various Bacillus subtilis
Mutants
To assess if EPS isolated from B. subtilis mutants had similar epitopes to WT
EPS, modified western SDS-PAGE was performed. Samples of pre-column EPS were
prepared as described previously and samples were boiled for 10 min at 95°C. A 5%
stacking gel and 10% resolving gel were prepared and a total volume of 30µL was loaded
onto a western SDS-PAGE apparatus consisting of 5µL of 6X sample buffer, and 25µL
of a 1mg/mL sample of EPS. EPS samples were run at 100 Volts (V) for 1.5 hr and
transferred to nitrocellulose membrane (LifeTechnologies) O/N at 100mA at 4°C. Free
binding sites on nitrocellulose membranes were blocked with 5% skim milk in 1X TBST
for 2 hr and incubated with a 1:10000 dilution of 1mg/mL primary rabbit anti-EPS serum
Ab in 1X TBST with 5% bovine serum albumin (BSA). Nitrocellulose membranes were
treated with a 1:10000 dilution of a 1mg/mL secondary horseradish peroxidaseconjugated goat anti-rabbit IgG (LifeTechnologies) in 1X TBST with 5% BSA for 30
min Immunoblots were developed using Immun-Star HRP (BioRad).

EPS Binding to Peritoneal Cells
To assess the level of binding of EPS from B. subtilis mutants to macrophages
(MΦ) isolated from the peritoneal cavity, cells from the peritoneal cavity were analyzed
by flow cytometry using a BD FACSCanto II flow cytometer. Approximately 2 million
cells were collected from C57Bl/6 mice by peritoneal lavage and red blood cells lysed by
a 5 min incubation with ammonium-chloride-potassium (ACK) Lysing Buffer
(LifeTechnologies). Cells were washed once in 1mL of FACS buffer, 1X PBS, 10% Fetal
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Calf Serum (FCS), and pelleted by centrifugation at 300 x g for 5 min. Pellets were resuspended in a volume of 100µL FACS buffer. One µL of 1mg/mL EPS was added to the
cells and incubated for 30 min at 4°C. Samples were washed with 2mL FACS buffer and
the pellet re-suspended in 100µL. One µL of 1mg/mL rabbit anti-EPS serum Abs was
added to samples and incubated for 30 min at 4°C. Cells were washed with 1mL of FACS
buffer and the pellet re-suspended in 100µL. Cells were stained for the presence of
macrophage markers with 1µL of a 1mg/mL rat anti-mouse F4/80 (BioLegend, Catalog
#123117) MΦ marker conjugated to allophycocyanin (APC) and 1µL of a 1mg/mL goat
anti-rabbit IgG Ab conjugated to fluorescein isothiocyanate (FITC) (Lifetechnologies,
Catalog#65-6111), and incubated for 30 min at 4°C. Tubes were washed with FACS
buffer and the pellet re-suspended in a final volume of 300µL of FACS buffer. Samples
were analyzed by flow cytometry using the BD LSRFortessa or BD FACSCanto II flow
cytometers; data were analyzed by the Flow Jo flow cytometry program.

Polysaccharide Composition Enzyme Assay
To identify the monosaccharide composition of EPS produced by B. subtilis
mutants, EPSs were assayed for percentage of D-mannose, D-Fructose, and D-Glucose as
described with slight modifications by Gawehn et. al. (Gawehn 1988). Briefly, 30µL of
10mg/mL EPS was treated with 4M trifluoroacetic acid (TFA) for 18 hr at 95°C
(Biermann 1988; Fengel and Wegener 1979; Galanos, Lüderitz, Himmelspach 1969).
Samples were dried and re-suspended in 10µL of 0.1M Tris. Enzyme reactions were
carried out in a 200µL total reaction volume. In a 96-well micotiter dish, 188µL of
45.6mM triethanolamine buffer (TEA), 2µL of 3µg/µL EPS, 2µL of 0.55mM adenosine
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tri-phosphate (ATP), 2µL of 0.36mM nicotinamide adenosine-di-phosphate (NADP),
and 2µL of 4.6U/mL hexokinase was added to each well and measured for base
absorbance at 340 nm.

TEA$Buffer$
Triethanolamine!
45.6 mM!
MgCl2!
6.4 mM!
β-Mercaptoethanol 1.3 mM!

Enzyme preparations of 2µL 0.9U/mL of Glucose-6-Phosphate Dehydrogenase
(G6PDH), 2µL of 2.3U/mL Phosphoglucose Isomerase (PGI), and 2µL of 4U/mL
Phosphomannose Isomerase (PMI) was added in succession and incubated at RT for 20
min, 10 min, and 30 min respectively and absorbance measured at 340 nm at each step.

Figure 2. Illustration of the enzymatic reactions in a monosaccharide composition
assay. HK – Hexokinase, G6P-DH – Glucose-6-Phosphate Dehydrogenase, PGI –
Phosphoglucose Isomerase, PMI – Phosphomannose Isomerase
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Mice
All animal experiments were performed according to protocols approved by the
Institutional Animal Care and Usage Committee at Loyola University Medical Center,
Maywood, IL. C57BL/6 founders were from Charles River Laboratory (Wilmington,
MA), and mice utilized for experiments (4 to 6 weeks of age) were bred at Loyola
University, Chicago, IL. Sterile standard chow and tap water were given to mice ad
libitum.

Bacterial Strains and Spore Preparation
The 32 B. subtilis strains used in this study were provide by Dr. Daniel Kearns
(Indiana University, Bloomington, IN) and are as follows: wild-type NCBI 3610,
DK1943 (ΔepsA), DK1806 (ΔepsB), DK1807 (ΔepsC), DS4248 (ΔepsD), DS2152
(ΔepsE), DS4164 (ΔepsF), DS7499 (ΔepsG), DS6776 (ΔepsH), DK1758 (ΔepsI),
DS4166 (ΔepsJ), DK2055 (ΔepsK), DS7432 (ΔepsL), DS4901 (ΔepsM), DS4900
(ΔepsN), DK1759 (ΔepsO), DK1960 (ΔepsA ΔsinR ΔtasA), DK1821 (ΔepsB ΔsinR
ΔtasA), DK1822 (ΔepsC ΔsinR ΔtasA), DK7724 (ΔepsD ΔsinR ΔtasA), DS2369 (ΔepsE
ΔsinR ΔtasA), DS7722 (ΔepsF ΔsinR ΔtasA), DS7760 (ΔepsG ΔsinR ΔtasA), DS7148
(ΔepsH ΔsinR ΔtasA), DK1781 (ΔepsI ΔsinR ΔtasA), DS7723 (ΔepsJ ΔsinR ΔtasA),
DK2057 (ΔepsK ΔsinR ΔtasA), DS7761 (ΔepsL ΔsinR ΔtasA), DS7726 (ΔepsM ΔsinR
ΔtasA, DS7725 (ΔepsN ΔsinR ΔtasA), DK1782 (ΔepsO ΔsinR ΔtasA) and were
generated as described by Kearns et. al. (Kearns et al. 2005). Briefly, strains of B. subtilis
mutants were generated using insertion deletion with long flanking homology PCR and
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transformed into competent cells of B. subtilis strain PY79 and transferred to B. subtilis
strain 3610.
B. subtilis spores were generated via exhaustion (Monteiro et al. 2005). Briefly,
O/N bacterial starter cultures were diluted 1:100 in Difco sporulation medium (DSM);

Difco Sporulation Medium (DSM) – per liter
Bacto nutrient broth (Difco) 8
g
10% (w/v) KCl
10 mL
1.2% (w/v) MgSO4 • 7H2O
10 mL
NaOH, pH 7.6
1.5 µM
Ca(NO3)2
1
µM
MnCl2
0.01 µM
FeSO4
1
µM
and incubated for 48 hr 250 RPM at 37°C. Bacteria were pelleted at 5000 x g for 15 min
at 4°C and washed three times in ice-cold sterile water. Pellets were re-suspended in
sterile water and heat shocked at 68°C for 30 min to kill any remaining vegetative cells.
Samples were washed three times with ice-cold water and stored at 4°C. Spore
preparations were assessed for spore concentrations by culturing serial dilutions. On the
day of administration, 109 CFU B. subtilis spores were washed with ice-cold sterile water,
re-suspended in 200µL 1X PBS, and given to mice via oral gavage (o.g.).
For infection studies, C. rodentium ATCC 51459 was cultured for 16 hr in LB
media, washed once in 1X PBS and an infectious dose of 5X108 CFU was re-suspended
in 200µL of sterile PBS for administration to mice by o.g.
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Isolation and Identification of Bacteria Contained in Natto
Three brands of Natto (soybeans fermented with B. subtilis), Hiruzen (Natto 1),
Marukin (Natto 2), and Mizkan (Natto 3), were obtained from a local grocery store,
diluted in LB media and particulates removed. Samples were heat shocked for 45 min at
70°C and plated on LB media with 1.5% agar. Single colonies were selected and
analyzed using matrix assisted laser desorption ionization – time of flight mass
spectrometry (MALDI-TOF MS) (Bruker Daltonik Maldi Biotyper). Sample time of
flights were measured against clinical and research databases and scored for match to
most likely bacterial species (Bruker Research Database).

Citrobacter rodentium Disease Model
Specific-pathogen-free C57Bl/6 mice were orally administered B. subtilis spores
(109 in 200µL in 1X PBS) 24 hr prior to infection with 5X108 CFU of C. rodentium by
o.g. Age- and gender- matched mice were utilized for each experiment. To assess disease,
mice were euthanized 10-11 days post infection and tissues collected. Mouse feces were
collected and scored for degree of diarrhea. Fecal samples were scored as described
(Jones and Knight 2012) using a scale from 1 to 4 with a score of 1 = no diarrhea; 2 =
slightly soft stool - mild diarrhea; 3 = very soft stool - moderate diarrhea; 4 =unformed
stool - severe.
To measure colonization with B. subtilis, feces were homogenized in 500µL of
sterile 20% glycerol in 1X PBS, and serial dilutions were cultured on selective LB with
1.5% bacto agar to determine the total number of B. subtilis CFU. Vegetative cells were
killed by heating at 68°C for 30 min, and serial dilutions were plated onto LB medium
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plates to quantify the spores. Plates were incubated overnight at 37°C; the resulting
colonies are represented as the number of CFU per gram of feces.
To measure colonization by C. rodentium, feces taken 10-11 days post infection
were homogenized in 500µL of sterile 20% glycerol in 1X PBS, and serial dilutions were
cultured on selective MacConkey agar plates. Plates were incubated overnight at 37°C,
and only small colonies that displayed the characteristic pink center surrounded by a
white rim were counted. The level of colonization was calculated and expressed as the
number of CFU per gram of feces.
To assess for C. rodentium induced colonic alterations, distal colons from
euthanized mice were collected and fixed overnight in 10% formalin-buffered phosphate,
embedded in paraffin and hematoxylin and eosin (H&E) stained. Longitudinal tissue
sections were examined for epithelial hyperplasia and goblet cell loss with bright field
microscopy and photos taken.

Figure 3. Model of C. rodentium infection.
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Serum Inflammatory Chemokine ELISA
To assess the level of serum inflammatory keratinocyte chemoattractant (KC)
cytokine, enzyme-linked immunosorbent assays (ELISA) were performed. Mictrotiter
plates (96-well) were coated with 100µL of a 2.0µg/mL mouse KC capture antibody
(R&D Systems, Catalog #DY453, Part #840325) and incubated overnight at 4°C. Plates
were washed with ELISA washing buffer (0.05% Tween20 in 1X PBS) three times and
free binding sites blocked with 300µL of a 1X reagent diluent (R&D Systems, Catalog
#DY995) and incubated for 1.5 hr at RT. Plates were washed three times and 100µL of
serum samples and standards were added and incubated for 2 hr at RT. Plates were
washed three times and 100µL of a 200ng/mL biotin labeled rat anti-mouse KC detection
Ab in carbonate buffer (R&D Systems, Catalog #DY453, Part#840326) was added and
incubated for 2 hr at RT. Plates were washed three times and 100µL of a 200ng/mL
Streptavidin-HRP reagent (R&D Systems, Catalog #DY453, Part #893975) was added
and incubated at RT for 30 min. Plates were washed three times and 100µL of a working
concentration of 3,3’,5,5’-tetramethylbenzidine (TMB) (LifeTechnologies, Catalog #002023) was added and the absorbance measured at 405 nm. Concentrations of KC were
calculated against a standard solution of recombinant mouse KC (R&D Systems Catalog
#DY453, Part #840327).

Carbonate Buffer
Na2CO3
15 µM
NaHCO3
34.5 µM
pH 9.5
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Allergic Sensitization to Ovalbumin
To assess sensitization to ovalbumin, C57Bl/6 mice were orally gavaged with 109
CFU of B. subtilis spores at day -3, and -1. At day 0, mice were injected intraperitoneally
(i.p.) with 100µL ovalbumin (100µg/mL) in 1X PBS (OVA) (SIGMA Fraction V) and
100µL of 20mg/mL alum in 1X PBS (Thermo Scientific Catalog #77161, Lot
#OD182171). Blood from sensitized mice was collected at day 14 and sera was assessed
by ELISA for levels of IgG1 and OVA-specific IgG1.

Figure 4. Model of allergic sensitization to ovalbumin.

To measure levels of total IgG1 from sera of sensitized mice, 96-well microtiter
plates were coated with 100µL of a 2µg/mL rat anti-mouse IgG1 primary antibody in
carbonate buffer and incubated O/N at 4°C. Plates were washed three times with ELISA
washing buffer, blocked with 100µL of a 3% BSA in 1X PBS solution, and then
incubated for two hours at RT. Plates were washed three times and 100µL of a 500ng/mL
standard diluted in duplicate two-fold six times was added. Serum (100µL of 1:20000)
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was added and plates were incubated for 1 hr. at RT. Plates were washed three times
and 100µL of a 2µg/mL biotinylated rat anti-mouse IgG1 secondary antibody
(BioLegend, Catalog #406604) added and incubated for 1 hr at RT. Plates were washed
three times and 100µL of a 1:3000 Streptavidin-HRP solution added and incubated in the
dark at RT for 30 min. Plates were washed three times and 100µL of a working
concentration of 3,3’,5,5’-tetramethylbenzidine (TMB) added and absorbance measured
at 405 nm.
To measure levels of OVA-specific IgG1 from sera of sensitized mice, 96-well
microtiter plates were coated with 100µL of 10µg/mL OVA in carbonate buffer pH 9.2
and incubated O/N at 4° C. Plates were washed three times, blocked with 100µL of 3%
BSA in 1X PBS and incubated for 2 hr at RT. Plates were washed three times and 100µL
of serum (1:20,000) was added and plates were incubated for 1 hr. at RT. Plates were
washed three times and 100µL of a 2µg/mL biotinylated rat anti-mouse IgG1 secondary
antibody (Biolegend, Catalog #406604) added and incubated for 1 hr at RT. Plates were
washed three times and 100µL of a 1:3000 Streptavidin-HRP solution added and
incubated in the dark at RT for 30 min. Plates were washed three times and 100µL of a
working concentration of TMB added and absorbance measured at 405 nm.

Generation of Bone Marrow Derived Mast Cell (BMDMC) and Peritoneal Derived
Mast Cell (PDMC).
Peritoneal cells from C57Bl/6 mice were collected by peritoneal lavage in
Roswell Park Memorial Institute media (RPMI) (LifeTechnologies, Catalog #31800) with
1X RPMI additive and pelleted at 300 x g at 4°C for 5 min. For generation of BMDMCs,
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femurs and tibias from mice were harvested and bone marrow (BM) collected. Pellets
were washed once in RPMI and spun at 300 x g at 4°C for 5 min. Pellets were resuspended in 5mL cell culture medium (RPMI with additive and 10% FCS) and
transferred into a small cell culture flask. Cells were incubated at 37°C and 5% CO2.

10X RPMI Additive – per liter
L-glutamine (200mM)
120 mL
MEM Vitamin Solution (100X)
100 mL
Penicillin Streptomycin (10,000U/mL) 50 mL
Fungizone (250µg/mL)
20 mL
Non-Ess AA (100X)
100 mL
ESS AA (50X)
100 mL
Hepes (1M)
100 mL
Na Pyruvate (100mM)
100 mL
7.5% NaHOC3
260 mL
Gentamicin (50mg/mL)
30 mL
β-Mercaptoethanol
35 µL
Tissue culture grade H2O
70 mL

On day three, non-adherent cells were discarded and 5mL of medium with
30ng/mL SCF and 10ng/mL IL-3 was added and placed back into the incubator (37° C,
5% CO2). At day 6, 5mL of fresh medium was added with 30ng/mL SCF and 10ng/mL
IL-3 preparations to flasks. Cell cultures were assessed for mast cell purity by flow
cytometry and stained with FcεRIα and CD117 cell markers. At day 9 or 10,
approximately 300,000 non-adherent cells were assessed for purity by staining with
hamster anti-mouse FcεRI (BioLegend, Catalog #134314) in 100µL with 1µL of a
1mg/mL, rat anti-mouse CD117 (BioLegend, Catalog #105807), and rat ant-mouse
FcBlock (CD16/32) (BioLegend Catalog #101319). Samples were analyzed by flow
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cytometry using the BD LSRFortessa or BD FACSCanto II machines; data were
analyzed by the Flow Jo flow cytometry program.
To assess the morphology of BMDMC and PDMC, cells were washed in FACS
buffer and spun at 300 x g for 5 min. To visualize purified BMDMC or PDMCs,
approximately 200,000 purified cells were washed and suspended in 100µL of 1X
Tyrode’s buffer. Cells were spun on a glass slide with a cytospin centrifuge and fixed,
stained with Diff-Quick and morphology visualized on bright field microscopy.

1X Tyrode’s Buffer – per liter
Hepes
10 mM
NaCl
129 mM
CaCl2
1.86 mM
MgCl2
2.13 mM
Glucose
5.6 mM
BSA
1 g

Mast Cell Degranulation Assay
To assess mast cell degranulation 5mL of approximately 200,000 cells per mL of
BMDMC or PDMC in RPMI were treated with 5µL of 10mg/mL EPS. Cells were primed
with 2µg/mL of 1mg/mL IgE anti-DNP at 37°C O/N. BMDMC or PDMC were derived
as described previously. Cells were washed in 1X Tyrode’s buffer and spun at 1000 RPM
at (RT) for 5 min. Pellets were re-suspended in 100µL of 1X Tyrode’s buffer and 10µL
added in duplicate to a 96-well V-bottom plate. Serially diluted (20,000ng/mL,
2,000ng/mL, 200ng/mL, 20ng/mL and 2ng/mL) 2,4-dinitrophenol (DNP) were added to
each sample (10µL) and incubated at 37°C for 60 min. Plates were centrifuged at
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1000rpm for 5 min and 10µL of supernatant from V-bottom plate was transferred to a
flat bottom plate and the remaining supernatant aspirated. Pellets from V-bottom plates
were treated with 20µL of 0.5% Triton-X in 1X Tyrode’s buffer and transferred to a 96well flat bottom plates. A solution of p-Nitrophenyl-N-acetyl-beta-D-glucosaminidine (pNAG) substrate (50µL of 4mM) was added to each well in a 96-well plate containing
supernatant and cell lysate and incubated for 60 min at 37° C. Glycine (0.2M), pH 10.7
(150µL) was added to each well and the absorbance measured at 405 nm. To calculate
the percent of mast cell degranulation, the optical densities (O.D.) of samples were
multiplied twice and average cell supernatant was divided by average cell supernatant
and average cell lysate and multiplied by 100.

Figure 5. Equation for the calculation of percent of mast cell degranulation.

Figure 6. Illustration of mast cell degranulation assay; treatment, priming and
challenge.
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Statistical Analysis
The number of times experiments were repeated are as indicated in results.
Experiments were analyzed using Student’s t-test and error bars denote standard errors of
the mean (SEM). Differences were considered statistically significant if P was < 0.05. (*
= <0.05; ** = 0.01 ; *** = 0.001; **** = 0.0001). NS = not significant.
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CHAPTER THREE
RESULTS
Characterization of Biofilm Formation by Bacillus subtilis Mutants
B. subtilis from a WT undomesticated strain forms a robust biofilm and pellicle
while an ΔepsH mutant does not. The epsA-O operon encodes for enzymes that aid in the
formation of biofilms and pellicles (Branda et al. 2006). To assess if deletions of
individual genes in the epsA-O operon affected the ability of B. subtilis to form biofilms
or pellicles, pellicle and biofilm formation assays for each of the 15 gene strains were
performed. Deletions of 11 of these genes resulted in the loss of both pellicle and biofilm
formation. Four strains, ΔepsA, ΔepsB, ΔepsJ, and ΔepsO were still capable of forming a
full biofilm or pellicle in the absence of the strains’ corresponding deleted gene (Figures
7A and 8A). The biofilms produced by strains of ΔepsC, ΔepsI, ΔepsK, and ΔepsN B.
subtilis were capable of forming what look like weak biofilms but unable to form
pellicles. A complete lack of pellicle and biofilm formation was exhibited in ΔepsD,
ΔepsE, ΔepsF, ΔepsG, ΔepsH, ΔepsL, and ΔepsM strains (Figures 7A, 8A, and 9). Of
the strains quantitated for the strength of biofilm produced, only ΔepsJ formed a
statistically significant biofilm that was comparable to WT B. subtilis (Figure 9).
Deletion of sinR, a global repressor gene of the epsA-O operon, and tasA, an
extracellular protein, results in increased EPS production as well as increased release of
EPS into culture medium (Branda et al. 2006; Chu et al. 2006). Deletion of genes in the
epsA-O, in addition to sinR and tasA deletions, provides a means to study EPS produced
!
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by these mutant strains. These triple mutants, ΔepsA-O, ΔsinR, and ΔtasA, are
derivatives of B. subtilis DS991 (ΔtasA and ΔsinR). EPS from B. subtilis DS991 was
previously demonstrated to protect mice from C. rodentium-associated disease. Strains,
with three deletions to sinR, tasA and epsA-O gene demonstrated a reduced capacity to
form a biofilm (Figures 7B and 8B).
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Figure 7. Effect of deletion to genes in the epsA-O operon on biofilm and pellicle
formation in B. subtilis. Photos of biofilm columns represent phase contrast images of
colonies grown overnight on LB plates with 1.5% agar, showing effects of mutations in
the indicated genes on the formation of a biofilm. Photos from pellicle columns depict
top-down images of microtiter wells (24-well plate) in which cells were grown in LB
media for 24 hr at 37°C. All strains used are as indicated in Table 4. A. Biofilm and
pellicle formation of strains of B. subtilis with a single deletion to a gene of the epsA-O
operon. B. Biofilm and pellicle formation of strains of B. subtilis with a deletion to a gene
of the epsA-O operon, sinR, and tasA.
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Figure 8. Effect of deletion in genes of the epsA-O operon on biofilm and pellicle
formation in B. subtilis. A. Biofilm and pellicle formation of strains of B. subtilis with a
single deletion to a gene of the epsA-O operon. B. Biofilm and pellicle formation of
strains of B. subtilis with a deletion to a gene of the epsA-O operon, sinR, and tasA. All
strains are as indicated in Table 4. Data provided by our collaborator, Dr. Daniel Kearns,
Indiana University, Bloomington, IN.
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Figure 9. Effect of deletions of genes of the epsA-O operon on biofilm formation in B.
subtilis. Bars represent the average absorbance (550 nm) of crystal violet as a
measurement of biofilm in wells in a 96-well microtiter dish following aspiration, crystal
violet staining, and addition of ETOH. Bacterial cultures were grown in LB media and
incubated at 37°C for 24 hr. Strains used are as indicated in Table 4. Biofilms of B.
subtilis mutants were significant compared to ΔepsH when P<0.05(*) (Student’s t-test).
Error bars represent the SEM.

DNA Sequence Analysis of Genes of the epsA-O Operon and Comparison to
Homologous Genes
EPS produced by B. subtilis is thought to be synthesized by the enzymes encoded
in the epsA-O operon. To identify and compare genes of the epsA-O operon to
homologous genes, sequences of the epsA-O operon in B. subtilis strain NCBI 3610 were
obtained from the NCBI website. Amino acid sequences from all epsA-O operon genes
(epsA, epsB, epsC, epsD, epsE, epsF, epsG, epsH, epsI, epsJ, epsK, epsL, epsM, epsN,
epsO) were aligned with Escherichia coli and Staphylococcus aureus sequences using the
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basic local alignment search tool (BLAST) from the NCBI website. Of the 15 genes of
the epsA-O operon, 6 genes, epsD, epsE, epsF, epsH, epsJ, and epsL, have sequences that
suggest they code for a glycosyltransferase. Two genes, epsE and epsL seem to have bifunctional activity. Additionally, the remaining genes of the operon may code for
modulator of a tyrosine kinase, a tyrosine kinase, a UDP-sugar epimerase, a membrane
protein, 2 pyruvyl transferases, flippase, an acetyltransferase, and an aminotransferase
(Table 4) (Data provided by our collaborator, Dr. Daniel Kearns, Indiana University,
Bloomington, IN). The large number of glycosyltransferases suggest that carbohydrate
modification may play an important role in EPS production.

Characterization of EPS Produced by Bacillus subtilis Mutants
To assess the size of EPS synthesized by B. subtilis strains, samples of EPS were
run on a fast protein liquid chromatography apparatus with standards of multiple sizes to
provide points of reference. Nine different samples of over-producing and over-secreting
strains of B. subtilis with single deletions of genes of the epsA-O operon were used
including all strains with deletions of genes that encode for a putative glycosyltransferase;
ΔepsD, ΔepsE, ΔepsF, ΔepsH, ΔepsJ, and ΔepsL. Samples were run on a Superose 6
matrix, a composite of cross-linked agarose gel (GE Lifesciences), and fractions were
assayed for the presence of carbohydrates by the phenol sulfuric acid assay. All samples
eluted from the column at similar volumes, suggesting the size/shape of these
polysaccharides are generally similar to each other. The samples eluted between the IgG
(150kDa) and fructose standards, suggesting that EPS in all of the mutants is less than
150 kDa (Figure 10).
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Differences in the absorbance were found among the different forms of EPS,
suggesting that some forms of EPS, such as ΔepsM and ΔepsN, secrete more EPS than
other strains, such as ΔepsG or ΔepsH (Figure 10). We conclude that all B. subtilis
mutant strains tested make EPS that is similar in size to WT EPS.

Figure 10. Assessment of the size of EPS isolated from different B. subtilis strains.
Graph depicts the absorbance of fractions eluted from a size exclusion column with a
Superose 6 matrix. Samples of EPS from strains of B. subtilis are as indicated in Table 4.
Blue arrows represent standards of Blue Dextran (>2000kD), apoferritin (480kD), IgG
(150kD), and fructose which were used as reference points.

EPS from WT B. subtilis is composed of different monosaccharide constituents,
mannose (88%) and glucose (12%) (Jones et al. 2014). To assess if there were differences
in the carbohydrate composition of EPS isolated from different B. subtilis strains WT
EPS, and EPS from ΔepsH and ΔepsF strains were analyzed using an enzymatic test. WT
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EPS protects from disease caused by C. rodentium and EPS from ΔepsH does not. If
there are differences in the composition of EPS from protective and non-protective B.
subtilis strains, then it might help identify the type of monosaccharide important for
protection.
The enzymatic test measures the change in absorbance that is a result of NADPH
production from enzyme and monosaccharide interactions. Monosaccharides were
hydrolyzed

and

phosphorylated

by

Hexokinase

(HK).

Glucose-6-phosphate

dehydrogenase (G6PDH), which identifies glucose-6-phosphate as its substrate, and
phosphomannose isomerase (PMI), which identifies mannose-6-phosphate as its substrate,
were used to measure the levels of glucose and mannose in EPS from WT B. subtilis as
well as EPS from ΔepsH and ΔepsF. There were no discernable differences in glucose or
mannose content between the three EPS samples used (Table 1, A-C). These data
confirm our current knowledge of WT EPS and suggest that the composition of EPS from
two B. subtilis mutants is similar; however, this assay may not have a sufficiently high
level of sensitivity to identify differences.
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0 min

20 min

10 min

30 min

Hexokinase

Glucose

Fructose

Mannose

WT EPS

0.000

0.264

0.100

0.518

Sucrose

0.000

0.511

0.156

0.062

Mannose

0.000

0.041

0.002

0.835

Hexokinase

Glucose

Fructose

Mannose

WT EPS

0.000

0.243

0.021

0.155

ΔepsH

0.000

0.158

0.005

0.250

Sucrose

0.000

0.391

-0.004

0.022

Mannose

0.000

-0.019

0.001

0.340

Hexokinase

Glucose

Fructose

Mannose

WT EPS 1:8

0.000

0.081

0.009

0.087

WT EPS 1:4

0.000

0.135

0.004

0.139

WT EPS 1:2

0.000

0.235

0.014

0.355

ΔepsF 1:2

0.000

0.268

0.001

0.479

Sucrose

0.000

0.694

0.092

0.043

Mannose

0.000

0.024

0.011

0.782

A.

B.

C.
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Table 1. Determination of monosaccharide composition of EPS from B. subtilis
strains. Table values represent the absorbance of samples of EPS from strains of B.
subtilis. Strains of B. subtilis are as indicated in Table 4. Columns indicate the enzyme
used in reaction as well as time of reaction prior to measurement. Sucrose and Mannose
were used as positive and negative controls respectively. A. Absorbance of WT EPS B.
Absorbance of WT EPS and EPS from ΔepsH C. Absorbance of WT EPS and EPS from
ΔepsF. Samples were diluted as indicated (1:2, 1:4, and 1:8).!
EPS from WT B. subtilis characterized by gas chromatography and mass
spectroscopy suggests that WT EPS has multiple glycosyl linkage residues. Major
glycosyl linkage residues include a 2,6 linked Mannopyranosyl residue (2,6-Man) (31.8%
of total EPS), terminal mannopyranosoyl residue (t-Man) (29.9% of total EPS), and a 3
linked mannopyranosyl residue (2-Man) (15% of total EPS) (Jones et al. 2014). To assess
the composition of polysaccharide samples, with a more sensitive assay, and to identify
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linkages in EPS from B. subtilis strains, gas chromatography, mass spectrometry, and
NMR spectroscopy were performed on samples of EPS by our collaborator, Dr. Neil
Price, USDA. EPS from WT B. subtilis, as well as EPS from ΔepsE, ΔepsJ, and ΔepsM
strains were used. If there are large differences in the composition and linkages of EPS
from non-protective mutant strains of B. subtilis, such as ΔepsM, when compared to WT
B. subtilis or protective strains, such as ΔepsJ and ΔepsE, then the differences in
monosaccharide composition and linkages may identify important residues for protection.

Sample
Mannose (%) Glucose (%)
WT B. subtilis
73.87
26.13
ΔepsE
76.27
23.73
ΔepsJ
88.31
11.69
ΔepsM
82.14
17.86
Table 2. Percent composition of glucose and mannose from B. subtilis strains.
Compositional analysis by gas chromatography and mass chromatography. EPS from
strains are as indicated in Table 4. Data provided in collaboration with Dr. Neil P.J.
Price, NCAUR-ARS-USDA, Peoria, IL.

Figure 11. Primary repeating structure and linkage of EPS-J. Structure and linkage
of EPS from B. subtilis ΔepsJ. Structure was determined from data gathered by
permethylation linkage and NMR spectroscopy. Data provided in collaboration with Dr.
Neil P.J. Price, NCAUR-ARS-USDA, Peoria, IL

Samples of WT EPS had mannose and glucose levels consistent with previous
studies (Jones et al. 2014). Samples of EPS from B. subtilis mutants had levels of
mannose and glucose that were similar to WT EPS (Table 2). Additionally, preliminary
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NMR experiments and analysis on EPS from ΔepsJ suggests similar composition and
linkage that has been reported from WT EPS (Data not shown). These data confirm our
current knowledge of the composition of WT EPS and suggest that the composition of
EPS from B. subtilis mutants may be similar in monosaccharide composition, and in the
case of EPS from ΔepsJ, similar linkage (Figure 11).

Recognition of EPS Isolated from Bacillus subtilis Mutants by Anti-EPS Serum
WT EPS is recognized by polyclonal rabbit anti-EPS serum. To assess if EPS
from B. subtilis mutants produce EPS similar to WT EPS, a modified western blot was
performed. If EPS from B. subtilis strains is similar to WT EPS, then polyclonal rabbit
anti-EPS serum should also recognize EPS from other B. subtilis strains. All mutant
forms of EPS were recognized by polyclonal rabbit anti-EPS serum. This suggests that
EPS from B. subtilis mutants is relatively similar to WT EPS. Additionally, EPS samples
did not migrate into the stacking gel or resolving gel and are primarily at the interface
between buffer and stacking gel (5%) or interface between stacking gel and resolving gel
(8%). This suggests that EPS samples were too large or did not have a sufficient negative
charge to migrate into the gel (Figure 12).
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Figure 12. Modified western SDS-PAGE performed on EPS from B. subtilis strains.
Strains used are as indicated in Table 4. Blue line represents buffer/stacking gel interface.
Red line indicates stacking gel/resolving gel interface. Green line represents flagellar
protein complex.
Recognition of EPS by Peritoneal Cells
WT EPS binds to peritoneal cells and exerts an immunomodulatory effect (Jones
et al. 2014). EPS from a ΔepsH mutant binds to peritoneal cells less well than WT EPS.
Results from the characterization of EPS from B. subtilis strains suggest that EPS is made
by these strains and that it is similar in composition to WT EPS. To determine if EPS
from other B. subtilis strains binds to peritoneal cells, we performed flow cytometry and
assessed the binding of EPS to cells that had been incubated with EPS and rabbit antiEPS serum. Data suggest that EPS from B. subtilis strains binds the surface of peritoneal
cells at varying levels. EPS from ΔepsD, ΔepsE, ΔepsF, ΔepsG, ΔepsH, and ΔepsL bind
peritoneal cells similar to WT EPS (Figure 13). More EPS binding from ΔepsJ, ΔepsM,
and ΔepsN is found that with WT EPS. These data suggest that EPS binding to peritoneal
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cells is not dependent on the ability of the B. subtilis strain to form a biofilm as EPS
from ΔepsJ, a strain that does form a biofilm, and EPS from ΔepsM and ΔepsN, strains
that do not form biofilms, bind peritoneal cells (Figure 7A, Figure 8A, Figure 13).
EPS from ΔepsH was not previously believed to bind to peritoneal cells.
Additionally, EPS from B. subtilis strains used in this experiment was not column
purified. Taken together, these data suggest that pre-column purified EPS from a number
of B. subtilis mutants can bind to peritoneal cells. Alternatively, there may be something
in the pre-column sample that also binds peritoneal cells and is recognized by the rabbit
anti-EPS serum.
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Figure 13. Binding of EPS from B. subtilis strains to peritoneal cells. Flow cytometric
analysis of EPS binding to the surface of peritoneal cells from naïve C57Bl/6 mice.
Granulocytes were selected on forward and side scatter. The x-axis represents fluorescent
intensity of rabbit anti-EPS serum. The y-axis represents normalized cell count. EPS from
strains are as indicated in Table 4. FITC-conjugated goat anti-rabbit Ig was used to detect
rabbit anti-EPS Ab.
Genes in the epsA-O Operon are Required for Protection from the Enteric
Pathogen, Citrobacter rodentium
Mice treated with WT B. subtilis spores by oral gavage or WT EPS by
intraperitoneal injection and then infected with C. rodentium do not display characteristic
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symptoms of disease. Mice treated with spores or EPS from a ΔepsH mutant and then
infected with C. rodentium are not protected from C. rodentium-associated disease (Jones
and Knight 2012). To determine which genes encoded in the epsA-O operon are needed
to confer protection against C. rodentium, B. subtilis spores with a single gene from the
epsA-O operon deleted were given to mice by oral gavage and mice were infected with C.
rodentium. If certain genes in the epsA-O operon are required to produce a protective
form of EPS, then mice treated with B. subtilis with deletions of the genes of the epsA-O
operon will not be protected from C. rodentium-associated disease.
All mice treated with B. subtilis had detectable levels of B. subtilis in their stool
five days post treatment. Additionally, all mice treated with C. rodentium had detectable
levels of the pathogen on day 10 of the experiment (Figure 15, A-B). These data suggest
that any symptoms of disease exhibited by mice were not due to lack of B. subtilis
persistence nor to a lack of colonization by the infectious pathogen, C. rodentium.
Furthermore, colonization with B. subtilis mutants did not seem to correlate with
protection, as spores of ΔepsJ and ΔepsK mutants were found at relatively high spore
concentrations in mice; however, disease markers suggest that ΔepsJ is protective while
ΔepsK is not (Figure 15A and Figures 16-17, A-D). Conversely, colonization with C.
rodentium did not correlate with disease severity, as mice treated with ΔepsA and ΔepsB
spores were colonized with a two fold difference of C. rodentium (Figure 15B), but
showed disease markers that were relatively the same (Figures 16-17, A-D, Figure 18).
Mice treated with WT B. subtilis spores do not develop loose and unformed
stools, while mice treated with ΔepsH spores do. Of the 15 mutant strains of B. subtilis
tested, 13 did not protect mice from developing diarrhea. Mice treated with B. subtilis
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spores of ΔepsE and ΔepsJ did not develop diarrhea (Figure 17C). In addition to
diarrhea, mice with C. rodentium-associated disease have enlarged spleens relative to
body weight. To assess if B. subtilis strains could protect from splenic inflammation, the
spleens of mice were harvested at day 10 or 11 post infection with C. rodentium. Of the
mice treated with B. subtilis mutants, 6 of 15 treatment groups did not have enlarged
spleens. Mice treated with B. subtilis mutants ΔepsE and ΔepsJ had spleen to body
weight ratios similar to PBS control (Figure 17D).
The large intestines from mice infected with C. rodentium exhibit changes to the
colonic architecture. These changes include elongation of crypts of the large intestines,
crypt hyperplasia, (Mundy et al. 2005) and loss of goblet cells (Jones and Knight 2012).
Mice treated with WT B. subtilis spores do not have elongated crypts or lower levels of
goblet cells. Uninfected mice have a crypt height of approximately 200µm. Of the 15 B.
subtilis mutant strains tested, two, ΔepsE and ΔepsJ did not have signs of elongated
crypts or loss of goblet cells. Mice treated with ΔepsL spores had the largest crypt height;
and therefore, the most inflamed colons of all groups. Mice treated with spores of ΔepsE
and ΔepsJ also had no change to goblet cells over untreated mice (Figure 16, A-B).
From these data, we conclude that only two B. subtilis mutants, ΔepsE and ΔepsJ,
conferred complete protection, suggesting that most genes in the epsA-O operon are
necessary to produce a protective form of EPS.
Interestingly, mice treated with EPS from WT B. subtilis and infected with C.
rodentium have lower levels of the inflammatory chemokine KC. To assess for protection
against C. rodentium by B. subtilis spores, an ELISA to assay the level of KC in sera was
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performed. Data suggest that there is no correlation between protection and KC
cytokine in mice treated with B. subtilis spores (Figure 14 and Figures 16-17, A-D).

Figure 14. Levels of serum KC, an inflammatory chemokine, in mice treated with B.
subtilis spores and infected with C. rodentium. Assessment of B. subtilis spores on C.
rodentium-associated disease 10 days post-infection (dpi) of WT mice. B. subtilis strains
are as indicated in Table 4. Results are averages from at least 3 mice. Error bars represent
the SEM.
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Figure 15. Colonization of B. subtilis mutants and C. rodentium. Results are averages
from two independent experiments; a total of 6 mice were assessed. Error bars represent
the SEM. A. Persistence of spores of B. subtilis epsA-O mutants in the colon of mice for a
period of five days post oral gavage. B. Colonization of C. rodentium in feces of mice at
day 10 or 11.
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Figure 16. Effect of B. subtilis mutants on C. rodentium-associated disease 10 days
post-infection. Infection-induced alterations in colon which were quantified by
measuring crypt heights and goblet cells per crypt height. Results are averages from two
independent experiments; a total of 6 mice were assessed for each group. Error bars
represent the SEM. A. Distal sections of fixed colons were measured for crypt height.
Columns at or below red bar suggest no C. rodentium-associated disease. B. Number of
goblet cells per crypt height. Columns at or above red bar suggest no C. rodentiumassociated disease. Treatments with B. subtilis spores and infection with C. rodentium
were compared to naïve mice. Treatments were significant compared to naïve untreated
mice when P< 0.05. Data were analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** =
0.001; **** = 0.0001; NS = not significant.
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Figure 17. Effect of B. subtilis mutants on C. rodentium-associated disease 10 days
post-infection. Infection-induced symptoms of C. rodentium-associated disease. C.
Diarrhea score D. Spleen to weight ratio. Results are averages from two independent
experiments; a total of 6 mice were assessed for each group. Error bars represent SEM.
Treatments with B. subtilis spores and infection with C. rodentium were compared to
naïve mice. Columns at or below red bar suggest no C. rodentium-associated disease
Treatments were significant compared to naïve untreated mice when P< 0.05. Data were
analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** = 0.001; **** = 0.0001; NS = not
significant.
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Figure 18. Representative photos of H&E stained longitudinal colonic sections from
mice treated with B. subtilis and infected with C. rodentium. Samples include
untreated mice (Naïve-PBS), B. subtilis and infected with C. rodentium (3610 + Cr), B.
subtilis mutants ΔepsE and ΔepsJ and infected with C. rodentium, and mice infected only
with C. rodentium. Black bars on the lower right hand corner indicate a measurement of
200µm. Data shown are representative of results from three independent experiments.
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Protection from C. rodentium-Associated Disease by Bacillus subtilis var. natto
Natto is a traditional fermented soybean dish eaten in a number of Asian
countries. Traditional Natto is fermented in the presence of B. subtilis var. natto and
these strains may confer protection against C. rodentium-associated disease.
Bacterial isolates from all three brands of Natto had similar colony morphology
with some being hazier than others and did not have the characteristic colony wrinkling
present in B. subtilis NCBI 3610 (Data not shown). By MALDI-TOF MS analysis, all
bacterial isolates were identified as B. subtilis (Table 2).
All mice treated with B. subtilis var. natto spores had detectable levels of B.
subtilis following treatment that were comparable to WT B. subtilis spores. Additionally,
all mice infected with C. rodentium were colonized with the pathogen at day 10 or 11.
These data suggest that mice were colonized by B. subtilis and C. rodentium (Figure
19B).
To assess protection from C. rodentium-associated disease, we measured the crypt
heights of mice treated with Natto spores and infected with C. rodentium. Mice receiving
spores from any of the 3 Natto isolates had on average, shorter crypt heights, more goblet
cells per crypt, and significantly better stool scores than mice infected with C. rodentium
alone. These data suggest that mice treated with B. subtilis from Natto were protected
from diarrhea and infection-induced alterations to the colon (Figure 20-21, A-C).
Additionally, the spleen to weight ratios of mice treated with Natto 1, Natto 2, and Natto
3 were similar to PBS controls and WT B. subtilis suggesting that mice treated with

!
!

!

!

! 61!

spores from Natto had significantly less systemic inflammation than mice treated with
C. rodentium alone (Figure 21D).
Although mice treated with Natto 3 spores had significantly reduced crypt
heights, their stool scores, reduced spleen to body weight ratio, and goblet cells per crypt
(Figure 19:1-2, A-D, Figure 21) suggest that mice treated with spores from Natto 3 were
protected. Collectively, these data suggest that a commercially available product can
protect against enteropathogenic disease; and more importantly, that some brands confer
more protection than others.

Table 3. MALDI-TOF MS analysis of bacteria isolated from Natto. All isolates with
different colony morphologies were selected for analysis. Analyte ID indicates product,
best match and second best match indicate the primary and secondary species. A Score
value >2 is significant to the species level (Bruker MALDI-TOF MS Research Database).
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Figure 19. Colonization of B. subtilis var. natto and C. rodentium. Results are averages
from two independent experiments; a total of 6 mice were assessed. Error bars represent
the SEM. A. Persistence of B. subtilis var. natto spores in the colon of mice for a period
of five days post oral gavage. B. Colonization of C. rodentium in feces of mice 10 or 11
dpi.
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Figure 20.!Effect of B. subtilis var. natto on C. rodentium-associated disease 10 days
post-infection. Infection-induced alterations in colon were assessed by measuring crypt
heights and goblet cells per crypt height. Results are averages from two independent
experiments; a total of 6 mice were assessed for each group. Error bars represent the
SEM. A. Distal sections of fixed colons were measured for crypt height. Bars at or below
red bar suggest no C. rodentium-associated disease. B. Number of goblet cells per crypt
height. Columns at or above red bar suggest no C. rodentium-associated disease.
Treatments with B. subtilis spores and infection with C. rodentium were compared to
naïve mice. Treatments were significant compared to naïve untreated mice when P<0.05.
Data were analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** = 0.001; **** =
0.0001; NS = not significant.
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Figure 21.!Effect of B. subtilis var. natto on C. rodentium-associated disease 10 days
post-infection. Infection-induced symptoms of C. rodentium-associated disease. C.
Diarrhea score and D. Spleen to weight ratio. Bars above the red line indicate no
protection. Columns at or below red bar suggest no C. rodentium-associated disease.
Results are averages from two independent experiments; a total of 6 mice were assessed
for each group. Error bars represent SEM. Treatments with B. subtilis spores and
infection with C. rodentium were compared to naïve mice. Treatments were significant
compared to naïve untreated mice when P<0.05. Data were analyzed by Student’s t-test, *
= <0.05; ** = 0.01; *** = 0.001; **** = 0.0001; NS = not significant.
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Figure 22. Representative photos of H&E stained longitudinal colonic sections from
mice treated with B. subtilis and infected with C. rodentium. Photos are representative
of colon sections from untreated mice (Naïve-PBS), treated with B. subtilis spores and
infected with C. rodentium (3610 + Cr), treated with B. subtilis var. natto spores and
infected with C. rodentium (Natto 1 + Cr, Natto 2 + Cr, or Natto 3 + Cr), and mice
infected only with C. rodentium. Black bars on the lower right hand corner indicate a
measurement of 200µm. Data shown are representative of results from three independent
experiments.
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Characterization of Immunomodulatory Effects of Protective EPS isolated from
B. subtilis mutants
Mice treated with WT B. subtilis spores or WT EPS and sensitized to OVA do not
develop OVA specific Abs (Swartzendruber and Knight, unpublished data). If strains of
B. subtilis are protective in a C. rodentium model of disease, then these same strains may
also display immunomodulation in other models. We tested if B. subtilis mutant strains
that are either protective or not protective in the C. rodentium disease model behave
similarly in the OVA sensitization model. WT and mutant B. subtilis spores from strains
ΔepsH, ΔepsF, and ΔepsJ were orally administered to mice 3 days prior to intraperitoneal

injection of OVA and after 14 days, we used ELISA to determine the level of serum IgG1
anti-OVA. We found that mice treated with spores from ΔepsJ strain had low levels of
IgG1 anti-OVA Ab, similar to that from mice treated with WT B. subtilis spores. In
contrast, mice treated with spores from ΔepsH and ΔepsF, strains that do not confer
protection against C. rodentium, did not decrease the level of IgG1 anti-OVA, compared
to mice that received no B. subtilis. Mice treated with ΔepsH had low OVA-specific
IgG1 and mice treated with ΔepsF had higher levels of OVA-specific IgG1. These data
suggest that a strain of B. subtilis protective against C. rodentium, ΔepsJ, is
immunomodulatory in a sensitization model. Interestingly, a strain of B. subtilis that did
not confer

protection

against

C. rodentium, ΔepsH,

seems

to

have some

immunomodulatory effect as there was a reduced level of OVA-specific Abs in serum
from these mice (Figure 23). Taken together, this preliminary experiment demonstrates
that strains of B. subtilis not protective in a C. rodentium model may still exert an
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immunomodulatory effect on the host, and that ΔepsJ, a strain protective in a C.
rodentium model, is also immunomodulatory in other models of study.

Figure 23. Serum levels of allergen specific IgG1 in sensitized mice. Absorbance of
OVA specific IgG1 serum levels of mice sensitized with spore preparations from WT B.
subtilis, ΔepsH, ΔepsF, and ΔepsJ. Error bars represent SEM.

Bacterial polysaccharides can modulate allergic responses (Meier, Bein, Jaques
1957) and mast cell cultures treated with WT EPS do not degranulate in an in vitro assay.
To investigate if strains of B. subtilis with immunomodulatory effects modify
degranulation in mast cells, BMDMCs or PDMCs (Figure 24) were treated with purified
EPS from ΔepsF and ΔepsJ. Interestingly, compared to naïve BMDMCs, BMDMCs
treated with EPS-J have a different morphology and do not degranulate (Figure 25, A-B).
The perimeter around EPS-J treated mast cells have what look to be small circular
morphologies while naïve mast cells have a characteristic granule appearance. This may
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suggest that mast cells treated with immunomodulatory EPS causes gradual movement
of mast cell granules to the perimeter of the cell.
Data from degranulation assays also suggest that there is a difference between
mast cells cultured from the bone marrow and mast cells cultured from the peritoneal
cavity. These preliminary experiments suggest that PDMCs seem to degranulate while
BMDMCs do not seem to degranulate. Additionally, both PDMCs and BMDMCs have
high absorbance following challenge and degranulation over naïve mast cells. This may
suggest that the granules themselves are different in composition as there is less
absorbance regardless if mast cells degranulated or not (Figures 26-27). Collectively,
these data suggest that EPS-J has immunomodulatory activity and that it somehow
modulates the morphology of mast cells and potentially their contents.

Figure 24. Purity of cultured PDMC and BMDMC isolated from the peritoneum.
Cells were stained with mast cell markers (CD117 and FcεRI). FACS plots represent
mast cell purity from peritoneal (PDMC) and bone marrow (BMDMC) isolated from the
peritoneal cavity of naïve C57Bl/6 mice.
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B.$

Figure 25. Representative photos of mast cells before and after treatment with EPSJ. Photos represent difference in morphology of naïve BMDMC (A.) and BMDMC
treated with EPS from ΔepsJ. BMDMCs in culture were cytospun on glass slides and
stained using Diff-Quick reagents. Images represent magnification at 100x. Red arrows
indicate circular objects found along the perimeter of mast cells.

Figure 26. Percent degranulation in a mast cell degranulation assay. Percent
degranulation (A.) and absorbance of lysate from degranulated PDMCs (B.). PDMCs
were cultured for 10 days, half were treated with purified EPS from B. subtilis ΔepsJ.
Cells were then treated with IgE anti-DNP and challenged with DNP.
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Figure 27. Percent degranulation in a mast cell degranulation assay. Percent
degranulation (C.) and absorbance of lysate from degranulated BMDMCs (D.).
BMDMCs were cultured for 10 days, half were treated with purified EPS from B. subtilis
ΔepsJ. Cells were then treated with IgE anti-DNP and challenged with DNP.
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Table 4. Characterization of B. subtilis mutants. Strain column indicates strain of B.
subtilis used. Mutation column indicates which genes are deleted in the strain. Proposed
function indicates the function of the deleted gene determined through BLAST.
Phenotype is determined by the morphology of B. subtilis. Biofilm is indicated by the
growth of bacteria and degree of opacity; ++ (strong biofilm), + (weak biofilm), and ---(no biofilm). Pellicle formation is indicated by formation of a biofilm at the air liquid
interface; ++ (strong pellicle), + (weak pellicle), and ----- (no pellicle). ETOH: Sup
precipitate are indicated as + (precipitate) or ---- (no precipitate) when a visible
precipitate formed after addition of EtOH (50% final) to supernatant from an overnight
culture of B. subtilis. Protection from disease is indicated as + (protection) or ---- (no
protection) when mice are protected by three of four symptoms of disease (diarrhea,
goblet cell loss, crypt hyperplasia, and spleen to weight ratio). WT = Wild Type; ND =
Not Determined; WM = Wrinkled Morphology; WFM = Wrinkled and Flat Morphology.
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CHAPTER FOUR
DISCUSSION
A Unique and Novel Approach to Studying Polysaccharide Biosynthesis
Carbohydrate polymers, specifically bacterial polysaccharides, have a wide
variety of uses in public, private, and academic settings. Presently, their compositions,
biosynthesis, and mechanisms of immunomodulation are poorly understood. This study
used a unique and novel approach to better understand the synthesis of a complex
polysaccharide and its immunomodulatory activity. Using numerous approaches,
investigators have tried to characterize the enzymes that are involved in the biosynthesis
of bacterial polysaccharides (Freitas, Alves, Reis 2011; Öner 2013; Rehm 2010; Roux et
al. 2015; Schmid, Sieber, Rehm 2015; Wang et al. 2000). To our knowledge, our study,
which focuses on changes to a complex polysaccharide and not the enzymes or genes
involved in its biosynthesis, is one of the first to investigate what changes occur to a
polysaccharide during its biosynthesis.

Summary of Findings
EPS from WT B. subtilis contributes to the formation of a robust biofilm and
pellicle, and protects against all disease markers of the murine enteropathogen C.
rodentium. A single deletion of the epsH gene of the epsA-O operon inhibits the ability of
B. subtilis to form a strong biofilm and protect mice from C. rodentium-associated
disease.
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with deletions of the genes encoded in the epsA-O operon were assessed for their
ability to form a biofilm or pellicle, and their ability to protect against C. rodentiumassociated disease. EPS purified from B. subtilis strains were characterized for their
physical and chemical properties.
The results from the biofilm and pellicle formation assays confirm that EPS is a
key component that contributes to the formation of a biofilm. Experiments that assess the
biofilm and pellicle formation of B. subtilis strains provide limited information on the
characteristics of EPS produced by these mutants. There is no correlation with the
formation of a biofilm following deletion of the genes in the epsA-O operon and
protection from C. rodentium. Spores of ΔepsE, a non-biofilm forming strain, or spores
of ΔepsJ, a biofilm forming strain, were both protective against C. rodentium-associated
disease. Therefore, the ability to form a biofilm is independent of protection.
Our results indicate that there is no single gene in the epsA-O operon responsible
for protection from the enteropathogen C. rodentium. Additionally, lack of protection
from C. rodentium is not due to the lack of a polysaccharide being produced. To our
knowledge, all B. subtilis mutants produce some form of polysaccharide. From
preliminary experiments, it also seems that the monosaccharide composition from ΔepsE,
ΔepsF, ΔepsH, ΔepsJ, and ΔepsM does not correlate with protection. Interestingly, EPS

from B. subtilis with a deletion to epsF, a glycosyltransferase, elutes from a size
exclusion column similar to EPS from WT B. subtilis. This is contrasted with EPS from a
ΔepsH mutant that elutes after WT EPS suggesting it is smaller in size. The use of EPS

from an epsF mutant may serve as a better negative control then EPS from an epsH
mutant as it elutes out more closely with WT EPS preparations.
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A closer analysis of the composition of EPS suggested that there was a high
degree of similarity in the mannose and glucose concentrations in mutant forms of EPS.
Conformational studies were completed using NMR spectroscopy and suggest that, from
the samples tested, (ΔepsE, ΔepsJ, and ΔepsM) the majority of EPS is made of mannose
and a minority is made of glucose. There does not seem to be a correlation with mannose
or glucose concentration and protection or immunomodulatory activity. Therefore,
protection by EPS is not due to the type or amount of monosaccharide found in EPS. The
glycosidic bonds present in protective forms of EPS, such as the α1,6-Man or α1,2-Man
that are present in EPS from ΔepsJ, may be key linkages for immune modulation. Studies
on the bonding profiles in EPS from ΔepsE, which is protective, and ΔepsF, which is not
protective, are already underway.
From preliminary NMR analyses of EPS from ΔepsJ, the data suggest that a long
polymer is present. Loss of any the enzymes encoded by the epsA-O operon may result in
altered EPS structure. These modifications could eliminate or mask residues important
for interaction with the immune system. These deletions could also eliminate or
drastically reduce EPS production or limit the stability of the polysaccharide such that it
degrades faster than normal. Until better understandings of either enzyme activity, or
differences between individual forms of EPS are elucidated, the protective residues will
remain a mystery.
Peritoneal cells collected from B57Bl/6 mice intraperitoneally injected with WT
EPS are believed to become anti-inflammatory alternatively-activated M2-Mϕ. Mice
treated with WT EPS developed higher levels of M2-Mϕ than mice treated with EPS
from ΔepsH. When peritoneal macrophages from mice treated with WT EPS are co-
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cultured with naive CD4+ T cells, in vitro T-cell proliferation is suppressed (Paynich
and Knight, unpublished data). Preliminary experiments using EPS from ΔepsJ, which is
protective against C. rodentium, and ΔepsF, which is not protective against C. rodentium,
suggest that ΔepsJ does skew cells of the peritoneal cavity to become M2-Mϕ and these
cells can suppress T cell proliferation while cells treated with ΔepsF cannot (Data not
shown). This experiment should also be repeated with EPS from ΔepsE. If EPS from
ΔepsE is protective against C. rodentium-associated disease, then it should also exert
immunomodulatory activities similar to WT EPS and EPS from ΔepsJ.
It is believed that glycosyltransferases, of which the epsA-O operon has six
putative genes (ΔepsD, ΔepsE, ΔepsF, ΔepsH, ΔepsJ, ΔepsL), are involved in the
synthesis of EPS. If glycosyltransferases are involved in the synthesis of EPS, then
deletion of these genes should result in loss of immunomodulatory activity. Surprisingly,
deletions of two putative glycosyltransferases, epsE and epsJ, did not affect protection.
Future studies may benefit from investigating the remaining 4 glycosyltransferases to
identify their activities and substrates. In terms of protection against C. rodentiumassociated disease, it does seem that the remaining 13 genes of the epsA-O operon are
required for protection. Of these 13 remaining gene products, 4 encode for
glycosyltransferases.
The lack of protection conferred by 13 of 15 B. subtilis mutants suggests that
multiple genes of the epsA-O operon are necessary to produce a protective form of EPS.
Enzymes produced by genes encoded in the epsA-O operon most likely act sequentially
to generate functional EPS. It is known that some enzymes, such as EpsB are dependent
on the activity of EpsA. Additionally, there may be additional bi-functional enzymes,
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such as EpsE, and the loss of multiple functions contributes to changes of EPS
produced (Guttenplan, Blair, Kearns 2010). Furthermore, gene products may directly
interact with each other, may produce necessary substrates for downstream enzymes, or
modify EPS in such a way that it is not recognized by other enzymes responsible for the
next stage of EPS synthesis. Elucidation of the order in which proteins act on the
formation of EPS would clarify the biosynthetic pathway of EPS, identify functionally
redundant enzymes, and contribute to our understanding of the biofilm matrix of B.
subtilis.
While some mutants do not confer protection in a C. rodentium-disease model,
such as ΔepsH spores, they may have immunomodulatory activity. In a model assessing
sensitization and development of IgG1, WT EPS or B. subtilis spores inhibited the
development of IgG1. As a negative control, mice were treated with spores from two
mutant groups that do not protect against C. rodentium-associated disease, ΔepsH and
ΔepsF. Treatment of mice with B. subtilis ΔepsH spores prevents these mice from

developing IgG1 antibodies and is similar to the suppression of IgG1 antibodies observed
with treatment of WT B. subtilis and ΔepsJ. Conversely, mice treated with ΔepsF, which
is not protective against C. rodentium, is also unable to suppress IgG1. Collectively, these
data suggest that there is a very specific component or structure of EPS that is interacting
with the host and perhaps, the component or structure of EPS needed for
immunomodulatory activity changes with the models and approaches employed to study
EPS. There may be multiple residues with immunomodulatory activity. Unique structures
of EPS that can suppress C. rodentium-associated disease may be different than those that
suppress the development of IgG1 antibodies.
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When EPS from strains of B. subtilis were tested for reactivity against rabbit
anti-EPS antibody, which was generated by immunization with WT EPS, all mutant
forms of EPS bound this Ab. This finding suggests that the polyclonal antibodies present
in rabbit anti-EPS serum recognize a similar form of residue on the multiple EPSs from
B. subtilis strains. This idea is corroborated with the NMR analysis of purified EPS from
ΔepsE, ΔepsJ, and ΔepsM mutants showing that the structures are very similar to each

other and to WT EPS. Additionally, there is a high degree of similarity in the sugar
linkages of at least one strain, ΔepsJ to WT EPS. Further analysis should focus on the
structural differences of protective forms of EPS compared to non-protective forms of
EPS.

Confirmation of Protective Strains and Future Models
The initial studies of protection mediated by EPS were in a C. rodentium model of
disease. Since these initial experiments, EPS has been shown to confer protection in an
anaphylaxis model of disease (Swartzendruber and Knight, unpublished data) and a
model of experimental autoimmune encephalitis (Osborne and Knight, unpublished data).
Other models of disease may prove useful in exploring the potential uses of EPS as a
therapeutic. Spores of B. subtilis from ΔepsE, ΔepsH, and ΔepsJ have some form of
immunomodulatory activity, and they may be beneficial for future studies. Additionally,
as previously mentioned, spores or purified EPS from ΔepsF may serve as a better
negative control than ΔepsH, which has demonstrated immunomodulatory activity in a
model of antigen sensitization.
In our model of infection with C. rodentium, treatment of mice with B. subtilis
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spores from WT, ΔepsE, and ΔepsJ mutants protected against disease. This model
mimics EPEC in humans and would be easy to modify in order to test an EHEC model of
disease using C. rodentium that expresses shiga toxin. Treatment of mice with these
spores and then infection with C. rodentium that expresses the stx phage, which carries
the genes encoding Shiga toxin, would provide further evidence for the protective ability
of EPS. Additionally, protection via EPS in this model would be of particular interest
because it would demonstrate that immunomodulation mitigates the damaging and
debilitating effects of Shiga toxin associated with EHEC. EHEC is a prevalent disease in
the United States (Crim et al. 2014) and identification of a new therapeutic would be of
value.
Finally, experiments have demonstrated that treatment of BMDMCs with WT
EPS prevents mast cells from degranulating when primed with IgE and challenged with
corresponding antigen (Swartzendruber and Knight, unpublished data). Preliminary
experiments suggest that mast cells treated with EPS from ΔepsJ also do not degranulate
mast cells. Additionally, mast cells treated with EPS from ΔepsJ look characteristically
different than untreated mast cells. BMDMCs treated with EPS from ΔepsJ appear
“glassy” with what appears to be granules outside the cell on/near the periphery. It is
possible that EPS causes slow release of granules, which would explain why no
degranulation occurs when sensitized cells are challenged with allergen at a later time
point. Future experiments that follow the morphological changes of mast cells over time
may provide support for this hypothesis and provide a timeline for EPS action.

!

!

!

! 79!

Potential Probiotics and Caution of Their Use
A number of probiotic strains of bacteria are either from heritage collections
isolated from the environment or mass-produced by industry. Depending on the handling
of these strains, there is the possibility of some level of variation if they are handled in a
way that favors certain characteristics/traits. All three strains of B. subtilis var. natto were
protective against C. rodentium-associated disease; however, there was variation in the
degree of protection as well as the phenotypic characteristics of these strains when grown
on petri dishes. Polysaccharides can vary greatly depending on the strain and substrates
used (Öner 2013). EPS contributes to the taste and texture of Natto and most likely, B.
subtilis strains are different between the different brands of Natto.
Selection of desired characteristics of bacteria that affect taste, texture, and smell
of fermented foods may be beneficial for product development; however, they may
irreparably harm the immunomodulatory effects of B. subtilis. Furthermore, studies using
bacteria from industry are hampered by the secrecy these companies maintain over
production of these ‘probiotic’ strains.
In previous work, mice that were treated with purified EPS and infected with C.
rodentium did not have an increase in serum KC inflammatory chemokine. In contrast,
mice treated with B. subtilis spores and then infected with C. rodentium had elevated
levels of KC. It was expected that treatment with spores would also inhibit serum KC
inflammatory chemokine but this was not the case. In fact, mice treated with WT B.
subtilis had levels of KC inflammatory chemokine similar to infection with C. rodentium
alone. These data highlight the complicated nature of using a live organism and highlight
the importance of delivering purified EPS. While probiotics, such as B. subtilis, may
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protect from pathogens, treatment with a live organism may have unintended
consequences to the host.
Probiotics are a benefit to society, however, the lack of understanding regarding
the mechanisms involved in protection is a problem associated with their use. We live in
an age where the dissemination of information is quick and easy, regardless of the
accuracy, and as probiotics are relatively un-regulated, they may harm those seeking
health and wellness.

Further Study of the Enzymes Encoded in the epsA-O Operon
This study was not focused on the enzymatic activities of the proteins encoded by
the epsA-O operon; however, a better understanding of the enzymes encoded by the epsAO operon will enhance our understanding of bacterial polysaccharide biosynthesis.
Alternatively, now that it is known that 13 of 15 genes of the epsA-O operon are
necessary for protection, future studies may benefit from strains of B. subtilis with
multiple gene deletions to better pinpoint and characterize EPS biosynthesis.
Genes of the epsA-O operon may be coupled in their production for EPS as is the
case in other polysaccharides such as Xanthan. Additionally, other studies have
demonstrated improved yield by overexpressing genes involved in bacterial
polysaccharide production (Galván et al. 2013). Application of these methods to EPS
synthesis may prove useful in the production of EPS.
Furthermore, GTSs are generally promiscuous in the substrates they utilize. If
GTSs in the epsA-O operon are promiscuous in substrate usage, this would also modify
the quality of EPS produced. Alternatively, alterations to the growth medium or
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substrates available to B. subtilis may produce EPS that is characteristically different
from B. subtilis grown in LB.

Optimization of Purified EPS and Polysaccharide Biosynthesis
Throughout this study, spores were used in place of purified EPS. Spores
germinate into vegetative cells and treatment with live organisms increases the number of
potential interactions occurring in the host as demonstrated in experiments that assessed
the level of serum KC inflammatory chemokine. Synthesis of polysaccharides in vitro are
described in the literature and provide a way to optimize and study the activities of single
enzymes involved in polysaccharide biosynthesis (Braat et al. 2006; Carignatto et al.
2011; Faijes and Planas 2007; Kobayashi 2007; Steidler et al. 2000; Woodward et al.
2010; Zhang et al. 2003). The additional products that B. subtilis produces may hamper
or counteract the protective effects exerted by EPS in such a way that EPS’s efficacy is
not as high as when it is delivered as a purified substance. Delivery of purified EPS
would therefore be an ideal approach for future studies. It would also be advantageous to
encapsulate EPS so it can bypass the gastric acid, and serve as an alternative therapy for
immunocompromised patients when administration of live organisms is contraindicated.
Currently, production of EPS yields 10-15mg/L. Concentrations using genetically
modified bacterial polysaccharide producing strains can be as high as 188g/L (Ruffing
and Chen 2006). The are numerous reports on the optimization and increased yield of
bacterial polysaccharides through various methods. Methods to increase EPS yield
include: increasing the pool of polysaccharide precursors (mannose and glucose for EPS),
over-expression of gene(s) involved in synthesis, insertion of multiple plasmids encoding
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enzymes needed for polysaccharide production, higher ethanol (v/v) during
precipitation, precipitation with the low molarity salts, and use of a better carbon source
to list a few (Schmid, Sieber, Rehm 2015; Thorne et al. 2000; Zhang et al. 2003). A
potential caveat to these optimization techniques is that EPS may lose its
immunomodulatory activity and thus any product should be tested for protective effects.

Analysis of the Properties of EPS Produced by Bacillus subtilis Mutants
The lack of simple methods for the analysis of polysaccharides has limited
research. Of the methods currently available for the analysis of polysaccharides,
combined use of various NMR techniques and mass spectrometry offer the best way to
study a number of properties including polysaccharide structure and composition (Bubb
2003; Roux et al. 2015).
NMR approaches used in this thesis have already proven useful for understanding
the structure of mutant forms of EPS. The forms of EPS identified enzymatically, and by
NMR, suggest there are relatively low and varying levels of glucose and mannose in the
samples of EPS tested. NMR analysis has also proven useful in demonstrating that a
single long polysaccharide may be present in samples tested. The structure of the
immunomodulatory carbohydrate, PSA from B. fragilis, was resolved through NMR
spectroscopy and provided information to show how surface-exposed charges could
interact with MHCII molecules (Baumann et al. 1992; Cobb et al. 2004; Kalka-Moll et al.
2002). Although EPS is not currently known to have a charge, elucidation of the structure
of EPS from various B. subtilis mutants will provide a better understanding of residues
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present and may help elucidate the roles that enzymes of the epsA-O operon play in
EPS biosynthesis.
Analyses by NMR and mass spectrometry will enable closer inspection of the
composition and types of residues found in samples of EPS and allow for comparison
between protective and non-protective forms of EPS. Elucidation of the components of
EPS produced by ΔepsJ, which behaves in a similar manner to WT EPS, shows a high
degree of similarity to WT EPS. EPS from ΔepsE, which is believed to be protective, and
ΔepsF, which is not believed to be protective, are ideal for further study.
While not typically used, pulse chase experiments, using radiolabeled carbon,
have been used successfully in the past to study bacterial polysaccharide synthesis
(Robyt, Yoon, Mukerjea 2008). Employing pulse chase methods, the first experiments
used radiolabeled 14C-sucrose successfully followed the transfer of sucrose molecules to
the reducing end of a growing dextran polymer.

Concluding Remarks
In summary, this work has sought to characterize a complex polysaccharide, EPS,
using strains of B. subtilis with deletions of the genes encoded in the epsA-O operon.
Through the use of a C. rodentium disease model, 13 genes of the epsA-O operon of B.
subtilis were identified as being necessary for prevention of inflammatory disease
induced by the enteric pathogen. Consistent with the idea that B. subtilis can provide
protection from disease, we isolated and identified B. subtilis in Natto products that also
protected mice from disease, thus providing a clinical approach towards treatment.
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Critically, Natto is a product that has been available for decades and is safe for human
consumption.
Collectively, these data highlight the complicated nature of bacterial
polysaccharide biosynthesis, demonstrate that protection is available from commercially
available sources, and provide a new avenue to study the enzymes needed for protection.
We can begin compositional studies to examine the similarities and differences of
protective EPS. Further study should help elucidate and advance the field of carbohydrate
polymer research, provide a rationale for further study of EPS from epsA-O operon
mutants, and may aid in identification of other bacterial EPSs with immunomodulatory
activity.
While this work has provided a better phenotypic understanding of EPS, the
immunomodulatory activity, and structural analysis of EPS are needed for a true
understanding of how these polysaccharides interact with the host.
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